


**CUMULATIVE
SUPPLEMENT 3
MARCH 2022**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2022

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

**Cumulative Supplement
March 2022**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

**CUMULATIVE SUPPLEMENT 3
MARCH 2022**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
HERITAGE PHARMACEUTICALS INC (HERITAGE PHARMS INC)	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC (HERITAGE PHARMS)
SANDOZ INC (SANDOZ)	EPIC PHARMA INC (EPIC PHARMA)
TELIGENT OU (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
TELIGENT PHARMA INC (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u>	<u>DEC</u>	<u>MAR</u>	<u>JUN</u>	<u>SEP</u>	<u>DEC</u>
<u>COUNTED</u>	<u>2021</u>	<u>2022</u>	<u>2022</u>	<u>2022</u>	<u>2022</u>

DRUG PRODUCTS LISTED SINGLE SOURCE	21133 2701 (12.8%)	21339 2716 (12.7%)
MULTISOURCE	18432 (87.2%)	18623 (87.3%)
THERAPEUTICALLY EQUIVALENT	18298 (86.6%)	18493 (86.7%)
NOT THERAPEUTICALLY EQUIVALENT	134 (0.6%)	130 (0.6%)
EXCEPTIONS ⁴	54 (0.3%)	53 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	13	11
NUMBER OF APPLICANTS	1190	1204

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET, FOR SUSPENSION;ORAL
>A> TRIUMEQ PD
>A> +! VIIV HLTHCARE EQ 60MG BASE;EQ 5MG BASE;30MG N215413 001 Mar 30, 2022 Mar NEWA

ABIRATERONE ACETATE

TABLET;ORAL
YONSA
+! SUN PHARM 125MG N210308 001 May 22, 2018 Feb CAHN

ABROCITINIB

TABLET;ORAL
CIBINQO
+ PFIZER 50MG N213871 001 Jan 14, 2022 Jan NEWA
+ 100MG N213871 002 Jan 14, 2022 Jan NEWA
+! 200MG N213871 003 Jan 14, 2022 Jan NEWA

ACETAMINOPHEN

SOLUTION;INTRAVENOUS
ACETAMINOPHEN
AP ! SANDOZ INC 1GM/100ML (10MG/ML) A204052 001 Mar 22, 2016 Feb CHRS
OFIRMEV
+ @ MALLINCKRODT HOSP 1GM/100ML (10MG/ML) N022450 001 Nov 02, 2010 Feb DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
>A> AA HIKMA 300MG;50MG;40MG A215135 001 Mar 25, 2022 Mar NEWA
>A> AA 325MG;50MG;40MG A215135 002 Mar 25, 2022 Mar NEWA
TABLET;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
>D> AA NESHOR PHARMS 325MG;50MG;40MG A211543 001 Jul 17, 2020 Mar DISC
>A> @ 325MG;50MG;40MG A211543 001 Jul 17, 2020 Mar DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE
AB HIKMA 300MG;50MG;40MG;30MG A215138 002 Jan 26, 2022 Jan NEWA
AB 325MG;50MG;40MG;30MG A215138 001 Jan 26, 2022 Jan NEWA
AB LGM PHARMA 300MG;50MG;40MG;30MG A076560 002 Jul 19, 2012 Jan CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
>D> AA ANDA REPOSITORY 120MG/5ML;12MG/5ML A089450 001 Oct 27, 1992 Mar CAHN
>A> AA MIKART 120MG/5ML;12MG/5ML A089450 001 Oct 27, 1992 Mar CAHN
TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
@ CHARTWELL 300MG;15MG A089997 001 Dec 28, 1994 Feb CAHN
@ 300MG;30MG A089998 001 Dec 28, 1994 Feb CAHN
@ 300MG;60MG A089999 001 Dec 28, 1994 Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
>D> AA ! ANDA REPOSITORY 325MG/15ML;7.5MG/15ML A040482 001 Sep 25, 2003 Mar CAHN
>A> AA ! MIKART 325MG/15ML;7.5MG/15ML A040482 001 Sep 25, 2003 Mar CAHN
TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
>D> AA ANDA REPOSITORY 325MG;7.5MG A040432 001 Jan 22, 2003 Mar CAHN
@ CHARTWELL 325MG;7.5MG A040248 001 Apr 28, 2000 Feb CAHN
@ 325MG;10MG A040248 002 Apr 28, 2000 Feb CAHN
>A> AA MIKART 325MG;7.5MG A040432 001 Jan 22, 2003 Mar CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL
OXYCODONE AND ACETAMINOPHEN

>A>	MIKART	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018	Mar	CAHN
>D>	MIKART INC	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018	Mar	CAHN

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS
ACETYLCYSTEINE

AP	ASPEN	6GM/30ML (200MG/ML)	A213693	001	Feb 03, 2022	Jan	NEWA
	@ EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Feb	DISC
AP	INDOCO	6GM/30ML (200MG/ML)	A215620	001	Feb 23, 2022	Feb	NEWA

ACYCLOVIR

OINTMENT; TOPICAL
ACYCLOVIR

>D>	AB	PRINSTON INC	5%	A212202	001	Nov 15, 2021	Mar	DISC
>A>		@	5%	A212202	001	Nov 15, 2021	Mar	DISC

SUSPENSION; ORAL
ACYCLOVIR

>A>	AB	AUROBINDO PHARMA LTD	200MG/5ML	A216331	001	Mar 31, 2022	Mar	NEWA
-----	----	----------------------	-----------	---------	-----	--------------	-----	------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

>D>		@ ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar	CAHN
>D>		@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar	CAHN
>A>		@ CHARTWELL INJECTABLE	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar	CAHN
>A>		@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar	CAHN

ALBUTEROL SULFATE

TABLET; ORAL
ALBUTEROL SULFATE
@ CHARTWELL RX

		EQ 4MG BASE	A072151	002	Dec 05, 1989	Feb	CMS1
--	--	-------------	---------	-----	--------------	-----	------

ALLOPURINOL

INJECTABLE; INJECTION
ALLOPURINOL

AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Jan	NEWA
----	------------------	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL
ALLOPURINOL

AB	HARMAN FINOCHEM	100MG	A214443	001	Mar 07, 2022	Feb	NEWA
AB		300MG	A214443	002	Mar 07, 2022	Feb	NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
OSEN

>D>	+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013	Mar	DISC
>A>	+	@	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013	Mar	DISC
>D>	+		EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013	Mar	DISC
>A>	+	@	EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013	Mar	DISC

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

AB	STRIDES PHARMA	100MG	A211354	001	Feb 18, 2022	Feb	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

SYRUP; ORAL
AMANTADINE HYDROCHLORIDE

>D>	AA	! ANDA REPOSITORY	50MG/5ML	A074028	001	Jun 28, 1993	Mar	CAHN
>A>	AA	! CHARTWELL RX	50MG/5ML	A074028	001	Jun 28, 1993	Mar	CAHN

AMIFOSTINE

INJECTABLE; INJECTION
AMIFOSTINE

>D>		@ AUROMEDICS PHARMA	500MG/VIAL	A204363	001	Jul 17, 2017	Mar	CAHN
>A>		@ EUGIA PHARMA SPECILTS	500MG/VIAL	A204363	001	Jul 17, 2017	Mar	CAHN

AMINO ACIDSINJECTABLE; INJECTION
NEPHRAMINE 5.4%

>D>	B BRAUN	5.4% (5.4GM/100ML)	N017766	001		Mar	DISC
>A>	@	5.4% (5.4GM/100ML)	N017766	001		Mar	DISC

AMINOCAPROIC ACIDSOLUTION; ORAL
AMINOCAPROIC ACID

>A>	AA	AGENIX	0.25GM/ML	A215510	001	Mar 23, 2022	Mar	NEWA
-----	----	--------	-----------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDETABLET; ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

AB	MICRO LABS	EQ 12.5MG BASE; 5MG	A211925	001	Feb 02, 2022	Jan	NEWA
AB		EQ 25MG BASE; 10MG	A211925	002	Feb 02, 2022	Jan	NEWA
AB	MYLAN PHARMS INC	EQ 12.5MG BASE; 5MG	A071297	002	Dec 10, 1986	Jan	CTEC
AB	!	EQ 25MG BASE; 10MG	A071297	001	Dec 10, 1986	Jan	CTEC

AMLODIPINE BESYLATESOLUTION; ORAL
NORLIQVA

+! CMP DEV LLC EQ 1MG BASE/ML

N214439 001 Feb 24, 2022 Feb NEWA

TABLET; ORAL

AMLODIPINE BESYLATE

	@	CHARTWELL RX	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan	CAHN
	@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan	CAHN
	@		EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan	CAHN
>D>	@	TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Mar	CMFD
>A>	AB		EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Mar	CMFD
>D>	@		EQ 5MG BASE	A076846	002	Jun 28, 2007	Mar	CMFD
>A>	AB		EQ 5MG BASE	A076846	002	Jun 28, 2007	Mar	CMFD
>D>	@		EQ 10MG BASE	A076846	003	Jun 28, 2007	Mar	CMFD
>A>	AB		EQ 10MG BASE	A076846	003	Jun 28, 2007	Mar	CMFD
		NORVASC						
AB	+	VIATRIS	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jan	CAHN
AB	+		EQ 5MG BASE	N019787	002	Jul 31, 1992	Jan	CAHN
AB	+	!	EQ 10MG BASE	N019787	003	Jul 31, 1992	Jan	CAHN

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

>D>	AB	TORRENT	EQ 5MG BASE; 40MG	A202517	001	Jan 08, 2014	Mar	DISC
>A>	@		EQ 5MG BASE; 40MG	A202517	001	Jan 08, 2014	Mar	DISC
>D>	AB		EQ 5MG BASE; 80MG	A202517	003	Jan 08, 2014	Mar	DISC
>A>	@		EQ 5MG BASE; 80MG	A202517	003	Jan 08, 2014	Mar	DISC
>D>	AB		EQ 10MG BASE; 40MG	A202517	002	Jan 08, 2014	Mar	DISC
>A>	@		EQ 10MG BASE; 40MG	A202517	002	Jan 08, 2014	Mar	DISC
>D>	AB		EQ 10MG BASE; 80MG	A202517	004	Jan 08, 2014	Mar	DISC
>A>	@		EQ 10MG BASE; 80MG	A202517	004	Jan 08, 2014	Mar	DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	TEVA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	A210876	001	Jan 31, 2022	Jan	NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210876	002	Jan 31, 2022	Jan	NEWA
AB		9.375MG; 9.375MG; 9.375MG; 9.375MG	A210876	003	Jan 31, 2022	Jan	NEWA
AB		12.5MG; 12.5MG; 12.5MG; 12.5MG	A210876	004	Jan 31, 2022	Jan	NEWA

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D>	AB	NESHER PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A207340	001	Oct 31, 2017	Mar	CAHN
>D>	AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A207340	002	Oct 31, 2017	Mar	CAHN
>D>	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A207340	003	Oct 31, 2017	Mar	CAHN
>D>	AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A207340	004	Oct 31, 2017	Mar	CAHN
>D>	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A207340	005	Oct 31, 2017	Mar	CAHN
>D>	AB		5MG; 5MG; 5MG; 5MG	A207340	006	Oct 31, 2017	Mar	CAHN
>D>	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A207340	007	Oct 31, 2017	Mar	CAHN
>A>	AB	ZYDUS PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A207340	001	Oct 31, 2017	Mar	CAHN
>A>	AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A207340	002	Oct 31, 2017	Mar	CAHN
>A>	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A207340	003	Oct 31, 2017	Mar	CAHN
>A>	AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A207340	004	Oct 31, 2017	Mar	CAHN

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Mar CAHN
>A>	AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Mar CAHN
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Mar CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS

APOKYN

AP	+	MDD US	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004	Feb CFTG
APOMORPHINE HYDROCHLORIDE							
AP		SAGE CHEMS	30MG/3ML (10MG/ML)	A212025	001	Feb 23, 2022	Feb NFTG

APREMILAST

TABLET;ORAL

APREMILAST

	@	AMNEAL	10MG	A211782	001	Jun 30, 2021	Jan DISC
	@		20MG	A211782	002	Jun 30, 2021	Jan DISC
	@		30MG	A211782	003	Jun 30, 2021	Jan DISC

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN		LUPIN	EQ 0.015MG BASE/2ML	A213068	001	Feb 07, 2022	Jan NEWA
AN		VISTAPHARM	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb NEWA

ARTESUNATE

POWDER;INTRAVENOUS

ARTESUNATE

+	!	AMIVAS	110MG/VIAL	N213036	001	May 26, 2020	Feb CAHN
---	---	--------	------------	---------	-----	--------------	----------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS

M.V.I. PEDIATRIC

+	@	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL; 5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL; 17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4M G/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920	001	Sep 21, 2000	Jan DISC
---	---	---------	--	---------	-----	--------------	----------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;INTRAVENOUS

M.V.I. ADULT

+	@	HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIA L;15MG/VIAL;0.005MG/VIAL;0.6MG/VIA L;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6M G/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/V IAL	N021625	001	Jan 30, 2004	Jan DISC
---	---	---------	---	---------	-----	--------------	----------

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+	@	HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;1 5MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG /5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG /5ML;10MG/5ML;0.15MG/5ML	N021643	001	Feb 18, 2004	Jan DISC
---	---	---------	--	---------	-----	--------------	----------

ASENAPINE

SYSTEM;TRANSDERMAL

SECUADO

>D>	+	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019	Mar CHRS
>A>	+	!	3.8MG/24HR	N212268	001	Oct 11, 2019	Mar CHRS
>D>	+	!	7.6MG/24HR	N212268	003	Oct 11, 2019	Mar CHRS
>A>	+		7.6MG/24HR	N212268	003	Oct 11, 2019	Mar CHRS

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	@	HIKMA INTL PHARMS	325MG;50MG;40MG	A086162	002	Feb 16, 1984	Mar CRLD
>A>	+	@	325MG;50MG;40MG	A086162	002	Feb 16, 1984	Mar CRLD

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ MAYNE PHARMA INC 325MG; 50MG; 40MG; 30MG

A203335 001 Oct 30, 2015 Jan DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

>D> @ GALT PHARMS

385MG; 30MG; 25MG

A075141 001 May 29, 1998 Mar CMFD

>A>

385MG; 30MG; 25MG

A075141 001 May 29, 1998 Mar CMFD

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AB HETERO LABS LTD III

EQ 150MG BASE

A212278 001 Feb 02, 2022 Jan NEWA

AB

EQ 200MG BASE

A212278 002 Feb 02, 2022 Jan NEWA

AB

EQ 300MG BASE

A212278 003 Feb 02, 2022 Jan NEWA

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

AP AMNEAL

0.5MG/5ML (0.1MG/ML)

A215342 001 Jan 26, 2022 Jan NEWA

AP +! HOSPIRA

0.5MG/5ML (0.1MG/ML)

N021146 001 Jul 09, 2001 Jan CMFD

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ MAYNE PHARMA INC 0.025MG; 2.5MG

A210789 001 Jun 03, 2020 Jan DISC

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+! MMT

2.1MG/0.7ML; 600MG/2ML

N021983 001 Sep 28, 2006 Jan CAHN

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP AMNEAL

100MG/VIAL

A211549 001 Feb 03, 2022 Jan NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

>D> AB AKORN

0.2055MG/SPRAY

A210032 001 Aug 23, 2019 Mar DISC

>A>

@

0.2055MG/SPRAY

A210032 001 Aug 23, 2019 Mar DISC

@ AMNEAL

0.2055MG/SPRAY

A208199 001 Dec 15, 2017 Jan DISC

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

>D> + ARBOR PHARMS LLC

EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011 Mar CAHN

>D>

+!

EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011 Mar CAHN

>A>

+

AZURITY

EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011 Mar CAHN

>A>

+!

EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011 Mar CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

>D> + ARBOR PHARMS LLC

EQ 40MG MEDOXOMIL; 12.5MG

N202331 001 Dec 20, 2011 Mar CAHN

>D>

+!

EQ 40MG MEDOXOMIL; 25MG

N202331 002 Dec 20, 2011 Mar CAHN

>A>

+

AZURITY

EQ 40MG MEDOXOMIL; 12.5MG

N202331 001 Dec 20, 2011 Mar CAHN

>A>

+!

EQ 40MG MEDOXOMIL; 25MG

N202331 002 Dec 20, 2011 Mar CAHN

BACLOFEN

GRANULES; ORAL

LYVISPAH

+ AMNEAL

5MG/PACKET

N215422 001 Nov 22, 2021 Feb CAHN

+

10MG/PACKET

N215422 002 Nov 22, 2021 Feb CAHN

+!

20MG/PACKET

N215422 003 Nov 22, 2021 Feb CAHN

INJECTABLE; INTRATHECAL

LIORESAL

AP	+	!	AMNEAL	0.05MG/ML	N020075	003	Nov 07, 1996	Feb	CAHN
AP	+	!		0.5MG/ML	N020075	001	Jun 17, 1992	Feb	CAHN
AP	+	!		2MG/ML	N020075	002	Jun 17, 1992	Feb	CAHN

SUSPENSION; ORAL

FLEQSUVY

	+	!	AZURITY	25MG/5ML	N215602	001	Feb 04, 2022	Feb	NEWA
--	---	---	---------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

BACLOFEN

AB			MANKIND PHARMA	5MG	A215885	001	Jan 25, 2022	Jan	NEWA
AB				10MG	A215885	002	Jan 25, 2022	Jan	NEWA
AB				20MG	A215885	003	Jan 25, 2022	Jan	NEWA

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA			ACELLA	100MG	A091310	001	Jan 16, 2015	Jan	CAHN
AA				200MG	A091310	002	Jan 16, 2015	Jan	CAHN
>D>	AA	!	THEPHARMANETWORK LLC	100MG	A040627	002	Mar 30, 2007	Mar	CMS1
	AA	!		100MG	A040627	002	Mar 30, 2007	Jan	CMS1
	AA	!		150MG	A040627	003	Sep 24, 2014	Jan	CMS1
>A>	AA	!		200MG	A040627	002	Jul 25, 2007	Mar	CMS1

BENZOYL PEROXIDE; TRETINOIN

CREAM; TOPICAL

TWYNEO

>D>		+	@ GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021	Mar	CMFD
>A>		+	!	3%;0.1%	N214902	001	Jul 26, 2021	Mar	CMFD
		+	@	3%;0.1%	N214902	001	Jul 26, 2021	Feb	CAHN
		+	@ SOL-GEL TECHNOLOGIES	3%;0.1%	N214902	001	Jul 26, 2021	Jan	DISC

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

>D>			ANDA REPOSITORY	25MG	A090473	001	Sep 15, 2010	Mar	CAHN
>D>	AA			50MG	A090473	002	Sep 15, 2010	Mar	CAHN
>A>			MIKART	25MG	A090473	001	Sep 15, 2010	Mar	CAHN
>A>	AA			50MG	A090473	002	Sep 15, 2010	Mar	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

>D>	AP		HIKMA FARMACEUTICA	1MG/ML	A090287	001	Aug 31, 2009	Mar	CHRS	
>A>	AP	!		1MG/ML	A090287	001	Aug 31, 2009	Mar	CHRS	
>D>			COGENTIN							
>D>	AP	+	!	AKORN	1MG/ML	N012015	001		Mar	DISC
>A>		+	@		1MG/ML	N012015	001		Mar	DISC

BETAINE

FOR SOLUTION; ORAL

BETAINE

AB			LUKARE MEDICAL LLC	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Jan	NEWA
----	--	--	--------------------	--------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB			TASMAN PHARMA	EQ 0.05% BASE	A215186	001	Feb 18, 2022	Feb	NEWA
----	--	--	---------------	---------------	---------	-----	--------------	-----	------

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB			GLENMARK PHARMS LTD	2.5MG;6.25MG	A215995	001	Jan 26, 2022	Jan	NEWA
AB				5MG;6.25MG	A215995	002	Jan 26, 2022	Jan	NEWA
AB				10MG;6.25MG	A215995	003	Jan 26, 2022	Jan	NEWA

BOSENTAN

TABLET; ORAL

BOSENTAN

>A>	@	CHARTWELL MOLECULAR	62.5MG	A210342	001	Jan 03, 2020	Mar CAHN
>A>	@		125MG	A210342	002	Jan 03, 2020	Mar CAHN
>D>	@	CIPLA	62.5MG	A210342	001	Jan 03, 2020	Mar CAHN
>D>	@		125MG	A210342	002	Jan 03, 2020	Mar CAHN

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT		APOTEX	0.15%	A078479	001	Jan 31, 2022	Jan NEWA
----	--	--------	-------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

>A>		BRIMONIDINE TARTRATE AND TIMOLOL MALEATE					
>A>	AB	SANDOZ INC	0.2%;EQ 0.5% BASE	A091087	001	Apr 04, 2022	Mar NFTG
		COMBIGAN					
>D>	+	ALLERGAN	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007	Mar CFTG
>A>	AB	+	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007	Mar CFTG

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

BRINZOLAMIDE

>D>	AB	BAUSCH	1%	A204884	001	Aug 18, 2021	Mar CAHN
>A>	AB	BAUSCH AND LOMB	1%	A204884	001	Aug 18, 2021	Mar CAHN

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

>A>	AT2	EUGIA PHARMA	EQ 0.09% ACID	A204813	001	Mar 18, 2022	Mar NEWA
		@ VISTAPHARM	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Feb CAHN

BUDESONIDE

CAPSULE, DELAYED RELEASE; ORAL

BUDESONIDE

@ NATCO

3MG

A206724	001	Nov 23, 2016	Jan CAHN
---------	-----	--------------	----------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

>A>		BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE					
>A>	AB	MYLAN	0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Mar NFTG
>A>	AB		0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Mar NFTG
		SYMBICORT					
>D>	+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Mar CFTG
>A>	AB	+	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Mar CFTG
>D>	+		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Mar CFTG
>A>	AB	+	0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Mar CFTG

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP		ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Feb CMFD
----	--	-------------	-----------	---------	-----	--------------	----------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

>D>		@ NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019	Mar CAHN
>A>		@ NOVOCOL PHARM	0.5%	A211096	001	Feb 19, 2019	Mar CAHN
		@ STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Feb CAHN
		@	0.5%	A091503	002	Oct 18, 2011	Feb CAHN
		BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
		@ STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Feb CAHN
		@	0.5%	A091487	001	Oct 18, 2011	Feb CAHN
		@	0.75%	A091487	003	Oct 18, 2011	Feb CAHN

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan	CTEC
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan	CTEC
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan	CTEC
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan	CTEC
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan	CTEC
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan	CTEC
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan	CTEC

BUPRENORPHINE HYDROCHLORIDE

@	ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Jan	DISC
@		EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jan	DISC
@		EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jan	DISC
@		EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jan	DISC
@		EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jan	DISC
@		EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jan	DISC
@		EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jan	DISC

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3	GRANULES	150MG	A215568	001	Feb 02, 2022	Jan	NEWA
AB3		300MG	A215568	002	Feb 02, 2022	Jan	NEWA
AB3	WOCKHARDT LTD	300MG	A202189	002	Jan 28, 2022	Feb	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	!	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Feb	CHRS
	@	MYLAN	7.5MG	A075467	002	Mar 28, 2001	Feb	DISC
AB		TEVA	15MG	A075022	003	Feb 28, 2002	Feb	CHRS

CABERGOLINE

TABLET;ORAL

CABERGOLINE

>D>	@	STRIDES PHARMA	0.5MG	A076310	001	Dec 29, 2005	Mar	CMFD
>A>	AB		0.5MG	A076310	001	Dec 29, 2005	Mar	CMFD

CAFFEINE CITRATE

SOLUTION;ORAL

CAFCIT

+	@	HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan	DISC
AA	!	EXELA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Jan	CHRS

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S

>A>	AP	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;30MG/100ML;60 0MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022	Mar	NEWA
-----	----	--------------------	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT		FRESENIUS KABI USA	17.6MG/100ML;325.3MG/100ML;119.3MG /100ML;643MG/100ML	A214623	001	Feb 18, 2022	Feb	NEWA
----	--	--------------------	--	---------	-----	--------------	-----	------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

>A>	AB	ATLANTIDE	12.5MG	A074532	001	Mar 28, 1997	Mar	CAHN
>A>	AB		25MG	A074532	002	Mar 28, 1997	Mar	CAHN
>A>	AB		50MG	A074532	003	Mar 28, 1997	Mar	CAHN
>A>	AB		100MG	A074532	004	Mar 28, 1997	Mar	CAHN
>D>	AB	WOCKHARDT LTD	12.5MG	A074532	001	Mar 28, 1997	Mar	CAHN
>D>	AB		25MG	A074532	002	Mar 28, 1997	Mar	CAHN
>D>	AB		50MG	A074532	003	Mar 28, 1997	Mar	CAHN
>D>	AB		100MG	A074532	004	Mar 28, 1997	Mar	CAHN

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

@ VGYAAN 200MG

A214328 001 Aug 16, 2021 Feb DISC

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

>A> AB ZHEJIANG JIUZHOU 100MG

A215591 001 Mar 31, 2022 Mar NEWA

>A> AB 200MG

A215591 002 Mar 31, 2022 Mar NEWA

>A> AB 400MG

A215591 003 Mar 31, 2022 Mar NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB RISING 12.5MG; 200MG; 50MG

A213212 001 Jan 25, 2022 Jan NEWA

AB 18.75MG; 200MG; 75MG

A213212 002 Jan 25, 2022 Jan NEWA

AB 25MG; 200MG; 100MG

A213212 003 Jan 25, 2022 Jan NEWA

AB 31.25MG; 200MG; 125MG

A213212 004 Jan 25, 2022 Jan NEWA

AB 37.5MG; 200MG; 150MG

A213212 005 Jan 25, 2022 Jan NEWA

AB 50MG; 200MG; 200MG

A213212 006 Jan 25, 2022 Jan NEWA

STALEVO 125

AB + ORION PHARMA 31.25MG; 200MG; 125MG

N021485 006 Aug 29, 2008 Jan CTEC

STALEVO 200

AB +! ORION PHARMA 50MG; 200MG; 200MG

N021485 004 Aug 02, 2007 Jan CTEC

STALEVO 50

AB +! ORION PHARMA 12.5MG; 200MG; 50MG

N021485 001 Jun 11, 2003 Jan CTEC

STALEVO 75

AB + ORION PHARMA 18.75MG; 200MG; 75MG

N021485 005 Aug 29, 2008 Jan CTEC

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

AP AMNEAL EQ 0.25MG BASE/ML

A215337 001 Jan 27, 2022 Jan NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

>D> AB ORCHID HLTHCARE EQ 500MG BASE

A065309 001 Sep 18, 2006 Mar DISC

>A> @ EQ 500MG BASE

A065309 001 Sep 18, 2006 Mar DISC

FOR SUSPENSION; ORAL

CEFADROXIL

>D> AB ORCHID HLTHCARE EQ 250MG BASE/5ML

A065307 002 Oct 16, 2006 Mar DISC

>A> @ EQ 250MG BASE/5ML

A065307 002 Oct 16, 2006 Mar DISC

>D> AB EQ 500MG BASE/5ML

A065307 003 Oct 16, 2006 Mar DISC

>A> @ EQ 500MG BASE/5ML

A065307 003 Oct 16, 2006 Mar DISC

TABLET; ORAL

CEFADROXIL

>D> AB ORCHID HLTHCARE EQ 1GM BASE

A065301 001 Sep 18, 2006 Mar DISC

>A> @ EQ 1GM BASE

A065301 001 Sep 18, 2006 Mar DISC

>D> ! TEVA PHARMS EQ 1GM BASE

A062774 001 Apr 08, 1987 Mar CTEC

>A> AB ! EQ 1GM BASE

A062774 001 Apr 08, 1987 Mar CTEC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

>A> QILU EQ 2GM BASE/VIAL

A203661 002 Mar 11, 2022 Mar NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP ASTRAL EQ 1GM BASE/VIAL

A212721 001 Jul 21, 2020 Jan CMFD

AP EQ 2GM BASE/VIAL

A212721 002 Jul 21, 2020 Jan CMFD

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

>A> @ CHARTWELL RX 125MG/5ML

A065236 001 Dec 08, 2005 Mar CAHN

>A> @ 250MG/5ML

A065236 002 Dec 08, 2005 Mar CAHN

>D> AB ORCHID HLTHCARE 125MG/5ML

A065284 002 Dec 30, 2005 Mar DISC

>A> @ 125MG/5ML

A065284 002 Dec 30, 2005 Mar DISC

>D> AB 250MG/5ML

A065284 001 Dec 30, 2005 Mar DISC

>A> @ 250MG/5ML

A065284 001 Dec 30, 2005 Mar DISC

FOR SUSPENSION;ORAL

CEFPROZIL

>D>	@	TEVA PHARMS	125MG/5ML	A065236	001	Dec 08, 2005	Mar CAHN
>D>	@		250MG/5ML	A065236	002	Dec 08, 2005	Mar CAHN

TABLET;ORAL

CEFPROZIL

>D>	AB	ORCHID HLTHCARE	250MG	A065267	001	Dec 19, 2005	Mar DISC
>A>	@		250MG	A065267	001	Dec 19, 2005	Mar DISC
>D>	AB		500MG	A065267	002	Dec 19, 2005	Mar DISC
>A>	@		500MG	A065267	002	Dec 19, 2005	Mar DISC

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS

CEFTAROLINE FOSAMIL

>D>	AP	APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Mar DISC
>A>	@		400MG/VIAL	A208075	001	Sep 21, 2021	Mar DISC
>D>	AP		600MG/VIAL	A208075	002	Sep 21, 2021	Mar DISC
>A>	@		600MG/VIAL	A208075	002	Sep 21, 2021	Mar DISC
>D>	AP	TEFLARO	400MG/VIAL	N200327	001	Oct 29, 2010	Mar CTEC
>A>	+	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	Mar CTEC
>D>	AP		600MG/VIAL	N200327	002	Oct 29, 2010	Mar CTEC
>A>	+		600MG/VIAL	N200327	002	Oct 29, 2010	Mar CTEC

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

>A>	AB	ATLANTIDE	EQ 125MG BASE	A065166	001	Jul 29, 2005	Mar CAHN
>A>	AB		EQ 250MG BASE	A065166	002	Jul 29, 2005	Mar CAHN
>A>	AB		EQ 500MG BASE	A065166	003	Jul 29, 2005	Mar CAHN
>D>	AB	WOCKHARDT	EQ 125MG BASE	A065166	001	Jul 29, 2005	Mar CAHN
>D>	AB		EQ 250MG BASE	A065166	002	Jul 29, 2005	Mar CAHN
>D>	AB		EQ 500MG BASE	A065166	003	Jul 29, 2005	Mar CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION

ZINACEF

AP	+	PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB	+	PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb CAHN
----	---	--------------------	--------------------	---------	-----	--------------	----------

CELECOXIB

CAPSULE;ORAL

CELECOXIB

@ UNICHEM

@

@

@

			50MG	A213301	001	Jan 12, 2021	Feb DISC
			100MG	A213301	002	Jan 12, 2021	Feb DISC
			200MG	A213301	003	Jan 12, 2021	Feb DISC
			400MG	A213301	004	Jan 12, 2021	Feb DISC

CEPHALEXIN

FOR SUSPENSION;ORAL

CEPHALEXIN

>D>	AB	ORCHID HLTHCARE	EQ 125MG BASE/5ML	A065326	001	Jul 10, 2006	Mar DISC
>A>	@		EQ 125MG BASE/5ML	A065326	001	Jul 10, 2006	Mar DISC
>D>	AB		EQ 250MG BASE/5ML	A065326	002	Jul 10, 2006	Mar DISC
>A>	@		EQ 250MG BASE/5ML	A065326	002	Jul 10, 2006	Mar DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

LIBRIUM

AB	+	VALEANT PHARM INTL	5MG	A085461	001		Jan CRLD
AB	+		10MG	A085472	001		Jan CRLD

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

@ ECR PHARMA

@

			EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007	Feb DISC
			EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007	Feb DISC

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

>A>	@	APPCO	10MG	A213590	001	Aug 31, 2020	Mar	CAHN
>A>	@		25MG	A213590	002	Aug 31, 2020	Mar	CAHN
>A>	@		50MG	A213590	003	Aug 31, 2020	Mar	CAHN
>A>	@		100MG	A213590	004	Aug 31, 2020	Mar	CAHN
>A>	@		200MG	A213590	005	Aug 31, 2020	Mar	CAHN
>D>	@	MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Mar	CAHN
>D>	@		25MG	A213590	002	Aug 31, 2020	Mar	CAHN
>D>	@		50MG	A213590	003	Aug 31, 2020	Mar	CAHN
>D>	@		100MG	A213590	004	Aug 31, 2020	Mar	CAHN
>D>	@		200MG	A213590	005	Aug 31, 2020	Mar	CAHN
AB		MSN	25MG	A214827	001	Jan 27, 2022	Jan	NEWA
AB			50MG	A214827	002	Jan 27, 2022	Jan	NEWA
AB			100MG	A214827	003	Jan 27, 2022	Jan	NEWA
AB			200MG	A214827	004	Jan 27, 2022	Jan	NEWA

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB		CHARTWELL RX	25MG	A211063	001	Feb 26, 2019	Jan	CAHN
AB			50MG	A211063	002	Feb 26, 2019	Jan	CAHN
AB		INVENTIA	25MG	A211320	001	Feb 09, 2022	Jan	NEWA
AB			50MG	A211320	002	Feb 09, 2022	Jan	NEWA
AB		SUNNY	25MG	A209068	001	Jan 25, 2022	Jan	NEWA
AB			50MG	A209068	002	Jan 25, 2022	Jan	NEWA
AB		TAGI	25MG	A212878	001	Feb 24, 2022	Feb	NEWA
AB			50MG	A212875	001	Feb 24, 2022	Feb	NEWA

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

>A>	AB	RISING	375MG	A213126	001	Apr 05, 2022	Mar	NEWA
>A>	AB		500MG	A213126	002	Apr 05, 2022	Mar	NEWA
>A>	AB		750MG	A213126	003	Apr 05, 2022	Mar	NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

>D>	AB	UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Mar	DISC
>A>		@	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Mar	DISC
	AB		EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jan	NEWA
>D>	AB		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Mar	DISC
>A>		@	EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Mar	DISC
	AB		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jan	NEWA

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

@ UNIV TX MD ANDERSON 4-100mCi/ML

A205690 001 Oct 29, 2015 Feb DISC

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

>A>	AT	PAI HOLDINGS PHARM	1%	A209975	001	Apr 05, 2018	Mar	CAHN
>D>	AT	TELIGENT	1%	A209975	001	Apr 05, 2018	Mar	CAHN

SOLUTION; TOPICAL

CICLOPIROX

>D>	AT	ACTAVIS MID ATLANTIC	8%	A078046	001	Sep 18, 2007	Mar	CAHN
>A>	AT	CHARTWELL RX	8%	A078046	001	Sep 18, 2007	Mar	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ CHARTWELL RX 200MG

A074100 001 Jan 31, 1995 Jan CAHN

@ 300MG

A074100 002 Jan 31, 1995 Jan CAHN

@ 400MG

A074100 003 Jan 31, 1995 Jan CAHN

@ 800MG

A074100 004 Jan 31, 1995 Jan CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

@	AMNEAL PHARMS	30MG	A204364	001	Dec 02, 2021	Feb	DISC
@		60MG	A204364	002	Dec 02, 2021	Feb	DISC
@		90MG	A204364	003	Dec 02, 2021	Feb	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan	CAHN
@		EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan	CAHN
@		EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan	CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

>A>	AP	PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Mar	NEWA
>A>	AP		EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Mar	NEWA
>D>		@ SAGENT PHARMS INC	EQ 2MG BASE/ML	A201851	001	Nov 06, 2020	Mar	CMFD
>A>	AP		EQ 2MG BASE/ML	A201851	001	Nov 06, 2020	Mar	CMFD

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

+	!	ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Jan	NEWA
---	---	----------	--------------	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB		ALEMBIC PHARMS LTD	250MG	A210459	001	Jan 31, 2022	Jan	NEWA
AB			500MG	A210459	002	Jan 31, 2022	Jan	NEWA

CLINDAMYCIN PHOSPHATE

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		ENCUBE	EQ 1% BASE	A215607	001	Jan 18, 2022	Jan	NEWA
----	--	--------	------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>A>	AT	PAI HOLDINGS PHARM	EQ 1% BASE	A206945	001	Dec 30, 2016	Mar	CAHN
>D>	AT	TELIGENT	EQ 1% BASE	A206945	001	Dec 30, 2016	Mar	CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB1		ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Feb	CTEC	
AB2		SOLARIS PHARMA CORP	1.2%;0.025%	A212845	001	Feb 10, 2022	Feb	NFTG	
		VELTIN							
AB2	+	!	ALMIRALL		N050803	001	Jul 16, 2010	Feb	CFTG
			ZIANA						
AB1	+	!	BAUSCH		N050802	001	Nov 07, 2006	Feb	CTEC

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

>A>	AB	AUROBINDO PHARMA LTD	2.5MG/ML	A214404	001	Mar 24, 2022	Mar	NEWA
-----	----	----------------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

CLOBAZAM

AB		MSN	10MG	A213404	001	May 11, 2021	Feb	CMFD
AB			20MG	A213404	002	May 11, 2021	Feb	CMFD

CLOBETASOL PROPIONATE

GEL; TOPICAL

CLOBETASOL PROPIONATE

>A>	AB	PAI HOLDINGS PHARM	0.05%	A208881	001	Mar 06, 2017	Mar	CAHN
>D>	AB	TELIGENT	0.05%	A208881	001	Mar 06, 2017	Mar	CAHN

LOTION; TOPICAL

CLOBETASOL PROPIONATE

>A>	AB	PAI HOLDINGS PHARM	0.05%	A208667	001	Nov 29, 2016	Mar	CAHN
>D>	AB	TELIGENT	0.05%	A208667	001	Nov 29, 2016	Mar	CAHN

		OINTMENT;TOPICAL							
		CLOBETASOL PROPIONATE							
>A>	AB	PAI HOLDINGS PHARM	0.05%		A208589	001	Jan 23, 2019	Mar	CAHN
>D>	AB	TELLIGENT	0.05%		A208589	001	Jan 23, 2019	Mar	CAHN
		SOLUTION;TOPICAL							
		CLOBETASOL PROPIONATE							
AT		SOLARIS PHARMA CORP	0.05%		A211240	001	Feb 17, 2022	Feb	NEWA
		@ TOLMAR	0.05%		A076977	001	Aug 05, 2005	Feb	DISC
		<u>CLONIDINE</u>							
		TABLET, EXTENDED RELEASE;ORAL							
		NEXICLON XR							
		ATHENA	EQ 0.17MG BASE		N022500	001	Dec 03, 2009	Feb	CMFD
		@	EQ 0.17MG BASE		N022500	001	Dec 03, 2009	Jan	CAHN
		@	EQ 0.26MG BASE		N022500	002	Dec 03, 2009	Jan	CAHN
		<u>CLONIDINE HYDROCHLORIDE</u>							
		TABLET, EXTENDED RELEASE;ORAL							
		CLONIDINE HYDROCHLORIDE							
		@ MAYNE PHARMA INC	0.1MG		A210680	001	Apr 30, 2018	Feb	DISC
		<u>COLCHICINE</u>							
		TABLET;ORAL							
		COLCHICINE							
>A>	AB	@ PAR PHARM INC	0.6MG		A203976	001	Aug 12, 2021	Feb	DISC
		STRIDES PHARMA	0.6MG		A209173	001	Mar 10, 2022	Mar	NEWA
		<u>COLESEVELAM HYDROCHLORIDE</u>							
		TABLET;ORAL							
		COLESEVELAM HYDROCHLORIDE							
AB		SPH	625MG		A213456	001	Jan 21, 2022	Jan	NEWA
		<u>COLESTIPOL HYDROCHLORIDE</u>							
		TABLET;ORAL							
		COLESTIPOL HYDROCHLORIDE							
AB		ZYDUS PHARMS	1GM		A215223	001	Mar 10, 2022	Feb	NEWA
		<u>CROMOLYN SODIUM</u>							
		SOLUTION;INHALATION							
		CROMOLYN SODIUM							
>D>		@ FERA PHARMS LLC	10MG/ML		A075437	001	Apr 21, 2000	Mar	CMFD
>A>	AN		10MG/ML		A075437	001	Apr 21, 2000	Mar	CMFD
		<u>CYCLOSPORINE</u>							
		EMULSION;OPHTHALMIC							
		CYCLOSPORINE							
AB		MYLAN	0.05%		A205894	001	Feb 02, 2022	Jan	NFTG
		RESTASIS							
AB	+!	ALLERGAN	0.05%		N050790	001	Dec 23, 2002	Jan	CFTG
		SOLUTION;ORAL							
		CYCLOSPORINE							
		@ MAYNE PHARMA	100MG/ML		A065054	001	Dec 18, 2001	Feb	DISC
		<u>CYTARABINE</u>							
		INJECTABLE;INJECTION							
		CYTARABINE							
AP		HONG KONG	20MG/ML		A208485	001	Feb 28, 2022	Feb	NEWA
		<u>DALTEPARIN SODIUM</u>							
		INJECTABLE;SUBCUTANEOUS							
		FRAGMIN							
>A>	+	PFIZER	10,000IU/4ML (2,500IU/ML)		N020287	012	Mar 15, 2022	Mar	NEWA
		<u>DANTROLENE SODIUM</u>							
		INJECTABLE;INJECTION							
		DANTROLENE SODIUM							
>D>		@ AUROMEDICS PHARMA	20MG/VIAL		A205239	001	Feb 18, 2016	Mar	CAHN
>A>		@ EUGIA PHARMA SPECCLTS	20MG/VIAL		A205239	001	Feb 18, 2016	Mar	CAHN

DAPAGLIFLOZIN

TABLET; ORAL

DAPAGLIFLOZIN

AB		ZYDUS PHARMS	5MG	A211582	001	Feb 22, 2022	Feb NFTG
AB			10MG	A211582	002	Feb 22, 2022	Feb NFTG
		FARXIGA					
AB	+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb CFTG
AB	+	!	10MG	N202293	002	Jan 08, 2014	Feb CFTG

DAPSONE

GEL; TOPICAL

DAPSONE

AB		MYLAN	7.5%	A213847	001	Feb 04, 2022	Jan NEWA
>A>	AB	SEEGPHARM SA	5%	A210178	001	Mar 31, 2022	Mar NEWA
AB		TORRENT	7.5%	A214722	001	Feb 10, 2022	Feb NEWA

TABLET; ORAL

DAPSONE

@ VIRTUS PHARMS

@

25MG

100MG

A204074	001	May 10, 2016	Jan DISC
A204074	002	May 10, 2016	Jan DISC

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPZURA RT

+	!	BAXTER HLTHCARE CORP	500MG/VIAL	N213645	001	Jan 25, 2022	Jan NEWA
---	---	----------------------	------------	---------	-----	--------------	----------

DEFERASIROX

GRANULE; ORAL

DEFERASIROX

>D>	AB	AMNEAL	90MG	A214194	003	Aug 02, 2021	Mar DISC
>A>		@	90MG	A214194	003	Aug 02, 2021	Mar DISC
AB		CIPLA	90MG	A215026	001	Feb 23, 2022	Feb NEWA
AB			180MG	A215026	002	Feb 23, 2022	Feb NEWA
AB			360MG	A215026	003	Feb 23, 2022	Feb NEWA

DEFERIPRONE

TABLET; ORAL

DEFERIPRONE

AB		HIKMA	1GM	A213239	002	Feb 08, 2022	Jan NFTG
AB	+	FERRIPROX					
AB	+	CHIESI	1GM	N021825	002	Jul 25, 2019	Jan CFTG

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

@ MAYNE PHARMA

@

0.15MG, N/A; 0.02MG, 0.01MG

0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG

A076916	001	Dec 29, 2008	Jan DISC
A077182	001	Jan 24, 2006	Jan DISC

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

>A>	AB	PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016	Mar CAHN
>D>	AB	TELIGENT	0.25%	A208101	001	Feb 25, 2016	Mar CAHN

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+	@	SUN PHARM	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb CAHN
+	@		EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb CAHN

DEXAMETHASONE

SOLUTION; ORAL

DEXAMETHASONE

>D>		!	HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983	Mar CRLD
>A>		+	!	0.5MG/5ML	A088248	001	Sep 01, 1983	Mar CRLD

TABLET; ORAL

DEXAMETHASONE

BP	+	HIKMA	0.5MG	A084611	001		Jan CRLD
----	---	-------	-------	---------	-----	--	----------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP +! FRESENIUS KABI USA EQ 4MG PHOSPHATE/ML A084916 001 Feb CRLD

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC
TOBRAMYCIN AND DEXAMETHASONE

AB PADAGIS US 0.1%; 0.3% A212715 001 Feb 11, 2022 Feb NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

@ PIRAMAL CRITICAL EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A214794 001 Sep 03, 2021 Feb DISC

DEXTROAMPHETAMINE

>A> SYSTEM; TRANSDERMAL
>A> XELSTRYM

>A> + NOVEN PHARMS INC 4.5MG/9HR N215401 001 Mar 22, 2022 Mar NEWA
>A> + 9MG/9HR N215401 002 Mar 22, 2022 Mar NEWA
>A> + 13.5MG/9HR N215401 003 Mar 22, 2022 Mar NEWA
>A> +! 18MG/9HR N215401 004 Mar 22, 2022 Mar NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

@ MAYNE PHARMA 5MG A076137 001 Jan 18, 2002 Feb DISC
@ 10MG A076137 002 Jan 18, 2002 Feb DISC
@ 15MG A076137 003 Jan 18, 2002 Feb DISC
>D> AB NESHER PHARMS 5MG A209111 001 Jun 27, 2017 Mar DISC
>A> @ 5MG A209111 001 Jun 27, 2017 Mar DISC
>D> AB 10MG A209111 002 Jun 27, 2017 Mar DISC
>A> @ 10MG A209111 002 Jun 27, 2017 Mar DISC
>D> AB 15MG A209111 003 Jun 27, 2017 Mar DISC
>A> @ 15MG A209111 003 Jun 27, 2017 Mar DISC

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

ARBOR PHARMS LLC 2.5MG A090533 001 Oct 25, 2011 Jan CTEC
7.5MG A090533 003 Oct 25, 2011 Jan CTEC
15MG A090533 005 Oct 25, 2011 Jan CTEC
20MG A090533 006 Oct 25, 2011 Jan CTEC
30MG A090533 007 Oct 25, 2011 Jan CTEC
>D> AA NESHER PHARMS 5MG A206588 001 Mar 28, 2016 Mar DISC
>A> @ 5MG A206588 001 Mar 28, 2016 Mar DISC
>D> AA 10MG A206588 002 Mar 28, 2016 Mar DISC
>A> @ 10MG A206588 002 Mar 28, 2016 Mar DISC
@ WINDER LABS LLC 2.5MG A212160 001 Jun 07, 2021 Jan DISC
@ 5MG A212160 002 Jun 07, 2021 Jan DISC
@ 7.5MG A212160 003 Jun 07, 2021 Jan DISC
@ 10MG A212160 004 Jun 07, 2021 Jan DISC
@ 15MG A212160 005 Jun 07, 2021 Jan DISC
@ 20MG A212160 006 Jun 07, 2021 Jan DISC
@ 30MG A212160 007 Jun 07, 2021 Jan DISC

DIAZEPAM

TABLET; ORAL
VALIUM

>D> AB + ROCHE 2MG N013263 002 Mar CAHN
>D> AB + 5MG N013263 004 Mar CAHN
>D> AB +! 10MG N013263 006 Mar CAHN
>A> AB + WAYLIS THERAP 2MG N013263 002 Mar CAHN
>A> AB + 5MG N013263 004 Mar CAHN
>A> AB +! 10MG N013263 006 Mar CAHN

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL
DICLOFENAC POTASSIUM

AB ANNORA PHARMA 50MG A215375 001 Mar 04, 2022 Feb NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

>D>	AB	AKORN	1%	A209484	001	Nov 21, 2018	Mar	CMKT
>D>	AB	CIPLA	1%	A209903	001	Aug 03, 2018	Mar	CTEC
>A>			1%	A209903	001	Aug 03, 2018	Mar	CTEC

SOLUTION;TOPICAL

DICLOFENAC SODIUM

>D>	AT	TWI PHARMS	1.5%	A202393	001	Nov 24, 2014	Mar	DISC
>A>		@	1.5%	A202393	001	Nov 24, 2014	Mar	DISC

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

@ GENE YORK PHARMS 10MG/ML

A212058 001 Apr 26, 2019 Feb DISC

DIGOXIN

ELIXIR;ORAL

DIGOXIN

>A>	AA	AMICI	0.05MG/ML	A215209	001	Mar 11, 2022	Mar	NEWA
-----	----	-------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

DIGOXIN

AB AUROBINDO PHARMA LTD 0.0625MG

A214982 001 Feb 08, 2022 Jan NFTG

AB 0.125MG

A214982 002 Feb 08, 2022 Jan NEWA

AB 0.25MG

A214982 003 Feb 08, 2022 Jan NEWA

LANOXIN

AB + CONCORDIA 0.0625MG

N020405 001 Sep 30, 1997 Jan CFTG

DILTIAZEM HYDROCHLORIDE

SOLUTION;INTRAVENOUS

DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

+ @ EXELA PHARMA 125MG/125ML (1MG/ML)

N215252 001 Oct 28, 2021 Feb DISC

+ @ 250MG/250ML (1MG/ML)

N215252 002 Oct 28, 2021 Feb DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

>D>	AP	HOSPIRA	50MG/ML	A040140	001	Nov 20, 1998	Mar	DISC
-----	----	---------	---------	---------	-----	--------------	-----	------

A040140 001 Nov 20, 1998 Mar DISC

>A>		@	50MG/ML	A040140	001	Nov 20, 1998	Mar	DISC
-----	--	---	---------	---------	-----	--------------	-----	------

A040140 001 Nov 20, 1998 Mar DISC

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

>D>	AP	! ATHENEX INC	5MG/ML	A074939	001	Apr 13, 1998	Mar	CAHN
-----	----	---------------	--------	---------	-----	--------------	-----	------

A074939 001 Apr 13, 1998 Mar CAHN

>D>		@ AUROMEDICS PHARMA	5MG/ML	A075769	001	Nov 27, 2002	Mar	CAHN
-----	--	---------------------	--------	---------	-----	--------------	-----	------

A075769 001 Nov 27, 2002 Mar CAHN

>A>	AP	! CHARTWELL INJECTABLE	5MG/ML	A074939	001	Apr 13, 1998	Mar	CAHN
-----	----	------------------------	--------	---------	-----	--------------	-----	------

A074939 001 Apr 13, 1998 Mar CAHN

>A>		@ EUGIA PHARMA SPECCLTS	5MG/ML	A075769	001	Nov 27, 2002	Mar	CAHN
-----	--	-------------------------	--------	---------	-----	--------------	-----	------

A075769 001 Nov 27, 2002 Mar CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

AB MAYNE PHARMA EQ 100MG BASE

A070173 001 May 31, 1985 Feb CMFD

AB EQ 150MG BASE

A070173 002 May 31, 1985 Feb CMFD

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AB UNICHEM EQ 250MG VALPROIC ACID

A214643 001 Feb 25, 2022 Feb NEWA

AB EQ 500MG VALPROIC ACID

A214643 002 Feb 25, 2022 Feb NEWA

DONEPEZIL HYDROCHLORIDE

>A>		SYSTEM;TRANSDERMAL						
-----	--	--------------------	--	--	--	--	--	--

>A>		ADLARITY						
-----	--	----------	--	--	--	--	--	--

>A>		+ CORIUM	5MG/DAY	N212304	001	Mar 11, 2022	Mar	NEWA
-----	--	----------	---------	---------	-----	--------------	-----	------

N212304 001 Mar 11, 2022 Mar NEWA

>A>		+!	10MG/DAY	N212304	002	Mar 11, 2022	Mar	NEWA
-----	--	----	----------	---------	-----	--------------	-----	------

N212304 002 Mar 11, 2022 Mar NEWA

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	CHARTWELL RX	5MG	A090425	001	May 31, 2011	Mar	CAHN
-----	----	--------------	-----	---------	-----	--------------	-----	------

A090425 001 May 31, 2011 Mar CAHN

>A>	AB		10MG	A090425	002	May 31, 2011	Mar	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

A090425 002 May 31, 2011 Mar CAHN

>D>	AB	PLIVA HRVATSKA DOO	5MG	A090425	001	May 31, 2011	Mar	CAHN
-----	----	--------------------	-----	---------	-----	--------------	-----	------

A090425 001 May 31, 2011 Mar CAHN

>D>	AB		10MG	A090425	002	May 31, 2011	Mar	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

A090425 002 May 31, 2011 Mar CAHN

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

AT	GLAND PHARMA LTD	EQ 2% BASE	A215660	001	Jan 27, 2022	Jan NEWA
----	------------------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	Jan NEWA
----	------------	-------------------------	---------	-----	--------------	----------

DOXAPRAM HYDROCHLORIDEINJECTABLE;INJECTION
DOXAPRAM HYDROCHLORIDE

>D>	AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar CAHN
>A>	AP	CHARTWELL INJECTABLE	20MG/ML	A076266	001	Jan 10, 2003	Mar CAHN

DOXAZOSIN MESYLATETABLET;ORAL
CARDURA

AB	+	VIATRIS	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jan CAHN
AB	+		EQ 2MG BASE	N019668	002	Nov 02, 1990	Jan CAHN
AB	+		EQ 4MG BASE	N019668	003	Nov 02, 1990	Jan CAHN
AB	+		EQ 8MG BASE	N019668	004	Nov 02, 1990	Jan CAHN
		DOXAZOSIN MESYLATE					
		@ CHARTWELL RX	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan CAHN
		@	EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan CAHN
		@	EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan CAHN
		@	EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan CAHN
>A>	AB	METHOD	EQ 1MG BASE	A212727	001	Mar 15, 2022	Mar NEWA
>A>	AB		EQ 2MG BASE	A212727	002	Mar 15, 2022	Mar NEWA
>A>	AB		EQ 4MG BASE	A212727	003	Mar 15, 2022	Mar NEWA
>A>	AB		EQ 8MG BASE	A212727	004	Mar 15, 2022	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL
CARDURA XL

+	VIATRIS	EQ 4MG BASE	N021269	001	Feb 22, 2005	Jan CAHN
+		EQ 8MG BASE	N021269	002	Feb 22, 2005	Jan CAHN

DOXEPIN HYDROCHLORIDECAPSULE;ORAL
DOXEPIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 50MG BASE	A210675	004	Mar 03, 2022	Feb NEWA
AB		EQ 75MG BASE	A210675	005	Mar 03, 2022	Feb NEWA
>A>	JUBILANT CADISTA	EQ 10MG BASE	A215483	001	Mar 14, 2022	Mar NEWA
>A>		EQ 25MG BASE	A215483	002	Mar 14, 2022	Mar NEWA
>A>		EQ 50MG BASE	A215483	003	Mar 14, 2022	Mar NEWA
>A>		EQ 75MG BASE	A215483	004	Mar 14, 2022	Mar NEWA
>A>		EQ 100MG BASE	A215483	005	Mar 14, 2022	Mar NEWA
AB	MANKIND PHARMA	EQ 10MG BASE	A215710	001	Feb 09, 2022	Jan NEWA
AB		EQ 25MG BASE	A215710	002	Feb 09, 2022	Jan NEWA
AB		EQ 50MG BASE	A215710	003	Feb 09, 2022	Jan NEWA
AB		EQ 75MG BASE	A215710	004	Feb 09, 2022	Jan NEWA
AB		EQ 100MG BASE	A215710	005	Feb 09, 2022	Jan NEWA

TABLET;ORAL

DOXEPIN HYDROCHLORIDE
@ STRIDES PHARMA

@		EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan CAHN
@		EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan CAHN

DOXERCALCIFEROLINJECTABLE;INJECTION
DOXERCALCIFEROL

AP	EUGIA PHARMA	2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022	Jan NEWA
AP		4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Jan NEWA

DOXYCYCLINECAPSULE;ORAL
DOXYCYCLINE

>D>	AB	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Mar DISC
>A>		@	EQ 150MG BASE	A200065	001	Feb 17, 2011	Mar DISC
		MONODOX					
AB	+	CHARTWELL RX	EQ 150MG BASE	N050641	004	Feb 17, 2022	Feb NEWA

DOXYCYCLINE HYCLATE

		CAPSULE;ORAL							
		DOXYCYCLINE HYCLATE							
>D>	AB	NESHER PHARMS	EQ 50MG BASE	A208263	001	Nov 22, 2021	Mar	DISC	
>A>		@	EQ 50MG BASE	A208263	001	Nov 22, 2021	Mar	DISC	
>D>	AB		EQ 100MG BASE	A208263	002	Nov 22, 2021	Mar	DISC	
>A>		@	EQ 100MG BASE	A208263	002	Nov 22, 2021	Mar	DISC	
		TABLET;ORAL							
		DOXYCYCLINE HYCLATE							
>A>	AB	@ EMCURE PHARMS LTD	EQ 100MG BASE	A209969	001	Nov 09, 2018	Jan	DISC	
		PRAXGEN	EQ 100MG BASE	A212487	001	Mar 30, 2022	Mar	NEWA	

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

		TABLET, EXTENDED RELEASE;ORAL							
		BONJESTA							
AB	+!	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016	Feb	CFTG	
		DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE							
AB		ACTAVIS LABS FL INC	20MG;20MG	A212472	001	Mar 01, 2022	Feb	NFTG	

DULOXETINE HYDROCHLORIDE

		CAPSULE, DELAYED REL PELLETS;ORAL							
		DRIZALMA SPRINKLE							
	+	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Feb	CAHN	
	+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Feb	CAHN	
	+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Feb	CAHN	
	+!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Feb	CAHN	

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

		TABLET;ORAL							
		EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE							
AB		HETERO LABS LTD V	600MG;200MG;300MG	A203053	001	Jan 24, 2022	Jan	NEWA	

EFINACONAZOLE

		SOLUTION;TOPICAL							
		EFINACONAZOLE							
AB		LUPIN LTD	10%	A212169	001	Mar 02, 2022	Feb	NEWA	

EFLORNITHINE HYDROCHLORIDE

		CREAM;TOPICAL							
		VANIQA							
	+	@ SKINMEDICA	13.9%	N021145	001	Jul 27, 2000	Feb	DISC	

ELIGLUSTAT TARTRATE

		CAPSULE;ORAL							
		ELIGLUSTAT TARTRATE							
AB		AIZANT	EQ 84MG BASE	A212463	001	Sep 08, 2021	Feb	CAHN	

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

		TABLET;ORAL							
		DESCOVY							
	+	GILEAD SCIENCES INC	120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022	Jan	NEWA	

ENALAPRIL MALEATE

		SOLUTION;ORAL							
		ENALAPRIL MALEATE							
>A>	AB	ALKEM LABS LTD	1MG/ML	A213714	001	Mar 30, 2022	Mar	NEWA	
	AB	ANNORA PHARMA	1MG/ML	A214467	001	Feb 24, 2022	Feb	NEWA	

ENALAPRILAT

		INJECTABLE; INJECTION							
		ENALAPRILAT							
>D>	AP	ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar	CAHN	
	AP		1.25MG/ML	A075634	001	Aug 22, 2000	Jan	CHRS	
>A>	AP	CHARTWELL INJECTABLE	1.25MG/ML	A075634	001	Aug 22, 2000	Mar	CAHN	
	AP	! HIKMA FARMACEUTICA	1.25MG/ML	A078687	001	Dec 23, 2008	Jan	CHRS	
	AP	HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000	Jan	CHRS	

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

@ ACTAVIS LABS FL INC

40MG

A209614 001 May 14, 2021 Feb DISC

XTANDI

+! ASTELLAS

40MG

N203415 001 Aug 31, 2012 Feb CTEC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

+! ENDO VENTURES

50MG/10ML (5MG/ML)

N213994 001 Oct 16, 2020 Feb CMFD

AP GLAND PHARMA LTD

50MG/ML (50MG/ML)

A216146 001 Feb 25, 2022 Feb NEWA

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

>A> +! BELCHER

10MG/10ML (1MG/ML)

N205029 002 Feb 04, 2022 Mar NEWA

>D> SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

>D> EPINEPHRINE

>D> +! BELCHER

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014 Mar CDFR

>A> +!

1MG/ML (1MG/ML)

N205029 001 Jul 29, 2014 Mar CDFR

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIGNOSPAN FORTE

+! DEPROCO

EQ 0.02MG BASE/ML;2%

A088389 001 Jan 22, 1985 Feb CRLD

LIGNOSPAN STANDARD

+! DEPROCO

EQ 0.01MG BASE/ML;2%

A088390 001 Jan 22, 1985 Jan CRLD

EPLERENONE

TABLET;ORAL

EPLERENONE

>A> AB KARTHA

25MG

A214663 001 Mar 23, 2022 Mar NEWA

>A> AB

50MG

A214663 002 Mar 23, 2022 Mar NEWA

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROMYCIN LACTOBIONATE

AP NEXUS PHARMS

EQ 500MG BASE/VIAL

A215290 001 Feb 14, 2022 Feb NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

>A> AP EUGIA PHARMA

10MG/ML

A216244 001 Mar 21, 2022 Mar NEWA

>A> AP

20MG/ML

A216244 002 Mar 21, 2022 Mar NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP HAINAN POLY

EQ 40MG BASE/VIAL

A215732 001 Feb 10, 2022 Feb NEWA

@ SUN PHARM

EQ 20MG BASE/VIAL

A200882 001 Mar 18, 2013 Feb CAHN

AP

EQ 40MG BASE/VIAL

A200882 002 Mar 18, 2013 Feb CAHN

ESTRADIOL

TABLET;ORAL

ESTRADIOL

@ MAYNE PHARMA

0.5MG

A040114 003 Mar 14, 1996 Feb DISC

@

1MG

A040114 001 Mar 14, 1996 Feb DISC

@

2MG

A040114 002 Mar 14, 1996 Feb DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

@ CHARTWELL RX

1MG

A091165 001 Jul 14, 2011 Jan CAHN

@

2MG

A091165 002 Jul 14, 2011 Jan CAHN

@

3MG

A091165 003 Jul 14, 2011 Jan CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28
ZOVIA 1/35E-28
@ MAYNE PHARMA

0.035MG; 1MG

A072721 001 Dec 30, 1991 Jan DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL
@ MAYNE PHARMA

0.035MG; 0.5MG

A070686 001 Jan 29, 1987 Jan DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21
MICROGESTIN 1.5/30
@ MAYNE PHARMA

0.03MG; 1.5MG

A075548 002 Jul 30, 2003 Jan DISC

MICROGESTIN 1/20
@ MAYNE PHARMA

0.02MG; 1MG

A075647 002 Jul 30, 2003 Jan DISC

TABLET; ORAL-28
MICROGESTIN FE 1.5/30
@ MAYNE PHARMA

0.03MG; 1.5MG

A075548 001 Feb 05, 2001 Jan DISC

MICROGESTIN FE 1/20
@ MAYNE PHARMA

0.02MG; 1MG

A075647 001 Feb 05, 2001 Jan DISC

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

@ MAYNE PHARMA 0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG A076629 001 Mar 18, 2010 Jan DISC

AB MYLAN 0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG A205069 001 Jun 22, 2018 Feb CMFD

AB 0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG A205069 001 Jun 22, 2018 Feb CAHN

TABLET, CHEWABLE; ORAL
FINZALA

AB TEVA PHARMS USA INC 0.02MG; 1MG A210087 001 Apr 07, 2020 Jan CMFD

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

@ AMNEAL PHARMS 0.02MG; 1MG A207514 001 Sep 11, 2017 Jan DISC

ETONOGESTREL

IMPLANT; IMPLANTATION
IMPLANON

@ ORGANON 68MG/IMPLANT N021529 001 Jul 17, 2006 Jan CAHN

NEXPLANON

+! ORGANON 68MG/IMPLANT N021529 002 May 31, 2011 Jan CAHN

FAMCICLOVIR

TABLET; ORAL
FAMCICLOVIR

>D> AB CIPLA 125MG A078278 001 Mar 21, 2011 Mar DISC

>A> @ 125MG A078278 001 Mar 21, 2011 Mar DISC

>D> AB 250MG A078278 002 Mar 21, 2011 Mar DISC

>A> @ 250MG A078278 002 Mar 21, 2011 Mar DISC

>D> AB 500MG A078278 003 Mar 21, 2011 Mar DISC

>A> @ 500MG A078278 003 Mar 21, 2011 Mar DISC

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE

@ AKORN 10MG/ML A076324 001 Nov 27, 2002 Feb CAHN

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

@ AKORN 10MG/ML A076322 001 Nov 27, 2002 Feb CAHN

FEBUXOSTAT

TABLET; ORAL
FEBUXOSTAT

>A> AB PRINSTON INC 40MG A206266 001 Mar 28, 2022 Mar NEWA

>A> AB 80MG A206266 002 Mar 28, 2022 Mar NEWA

FERRIC CARBOXYMALTOSE

SOLUTION; INTRAVENOUS
INJECTAFER

+! AM REGENT 100MG IRON/2ML (50MG IRON/ML) N203565 004 Feb 04, 2022 Feb NEWA

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL

ALLEGRA

@ CHATTEM SANOFI

60MG

N020625 001 Jul 25, 1996 Jan CAHN

@

60MG

N020625 001 Jul 25, 1996 Jan CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

@ MYLAN

EQ 0.5MG BASE

A208005 001 Jan 19, 2021 Feb DISC

AB

EQ 0.5MG BASE

A208005 001 Jan 19, 2021 Feb CAHN

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

@ CHARTWELL

50MG

A079164 001 Jul 09, 2009 Feb CAHN

@

100MG

A079164 002 Jul 09, 2009 Feb CAHN

@

150MG

A079164 003 Jul 09, 2009 Feb CAHN

FLUCYTOSINE

CAPSULE;ORAL

FLUCYTOSINE

AB STRIDES PHARMA

250MG

A212632 001 Apr 17, 2020 Feb CMFD

AB

500MG

A212632 002 Apr 17, 2020 Feb CMFD

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

>D> @ AUROMEDICS PHARMA

500MG/10ML (50MG/ML)

A202668 001 Jul 17, 2012 Mar CAHN

>D>

@

1GM/20ML (50MG/ML)

A202668 002 Jul 17, 2012 Mar CAHN

>D>

@

2.5GM/50ML (50MG/ML)

A202669 001 Jul 17, 2012 Mar CAHN

>D>

@

5GM/100ML (50MG/ML)

A202669 002 Jul 17, 2012 Mar CAHN

>A>

@ EUGIA PHARMA SPECLTS

500MG/10ML (50MG/ML)

A202668 001 Jul 17, 2012 Mar CAHN

>A>

@

1GM/20ML (50MG/ML)

A202668 002 Jul 17, 2012 Mar CAHN

>A>

@

2.5GM/50ML (50MG/ML)

A202669 001 Jul 17, 2012 Mar CAHN

>A>

@

5GM/100ML (50MG/ML)

A202669 002 Jul 17, 2012 Mar CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

>A> AB1 MICRO LABS

EQ 10MG BASE

A216232 001 Mar 29, 2022 Mar NEWA

>A> AB1

EQ 20MG BASE

A216232 002 Mar 29, 2022 Mar NEWA

>A> AB

EQ 40MG BASE

A216232 003 Mar 29, 2022 Mar NEWA

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

>D> @ MYLAN

1MG

A089804 002 Aug 12, 1988 Mar CAHN

>D>

@

2.5MG

A089804 003 Aug 12, 1988 Mar CAHN

>D>

@

5MG

A089804 004 Aug 12, 1988 Mar CAHN

>D>

@

10MG

A089804 001 Aug 12, 1988 Mar CAHN

>A>

@ PRASCO

1MG

A089804 002 Aug 12, 1988 Mar CAHN

>A>

@

2.5MG

A089804 003 Aug 12, 1988 Mar CAHN

>A>

@

5MG

A089804 004 Aug 12, 1988 Mar CAHN

>A>

@

10MG

A089804 001 Aug 12, 1988 Mar CAHN

>A> AB

TWI PHARMS

2.5MG

A215848 001 Apr 01, 2022 Mar NEWA

>A> AB

5MG

A215848 002 Apr 01, 2022 Mar NEWA

>A> AB

10MG

A215848 003 Apr 01, 2022 Mar NEWA

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

+! ALMIRALL

0.05%

N012806 002

Feb CTEC

FLURANDRENOLIDE

@ CINTEX SVCS

0.05%

A205342 001 Apr 13, 2016 Feb DISC

LOTION;TOPICAL

FLURANDRENOLIDE

@ CINTEX SVCS

0.05%

A205343 001 Dec 22, 2016 Feb DISC

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

	@ CHARTWELL RX	125MG	A075818	001	Sep 18, 2001	Jan	CAHN
--	----------------	-------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

LOTION;TOPICAL

CUTIVATE

>D>							
>D>	AB	+! FOUGERA PHARMS	0.05%	N021152	001	Mar 31, 2005	Mar DISC
>A>		+ @	0.05%	N021152	001	Mar 31, 2005	Mar DISC

FLUTICASONE PROPIONATE

>D>	AB	GLENMARK GENERICS	0.05%	A090759	001	May 02, 2011	Mar CHRS
>A>	AB	!	0.05%	A090759	001	May 02, 2011	Mar CHRS

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

	AB	BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb CMFD
--	----	----------------	-------	---------	-----	--------------	----------

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

>A>		@ ARTHUR GRP	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Mar CAHN
>A>		@	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Mar CAHN
>D>		@ PRAXGEN	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Mar CAHN
		@	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Feb DISC
>D>		@	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Mar CAHN
		@	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Feb DISC

FOSDENOPTERIN HYDROBROMIDE

POWDER;INTRAVENOUS

NULIBRY

>D>		+! ORIGIN	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021	Mar CAHN
>A>		+! SENTYNL THERAPS INC	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021	Mar CAHN

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL

FOSFOMYCIN TROMETHAMINE

	AA	CIPLA	EQ 3GM BASE/PACKET	A211881	001	Jan 26, 2022	Jan NEWA
--	----	-------	--------------------	---------	-----	--------------	----------

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

>A>	AB	ZENARA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Mar NEWA
-----	----	--------	---------------	---------	-----	--------------	----------

FULVESTRANT

INJECTABLE;INTRAMUSCULAR

FULVESTRANT

		@ APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Jan DISC
AO		JIANGSU HANSOH PHARM	50MG/ML	A214682	001	Feb 10, 2022	Feb NEWA
AO		ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Feb CMFD

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

>D>	AP	HONG KONG	10MG/ML	A212803	001	Jan 27, 2022	Mar CAHN
	AP		10MG/ML	A212803	001	Jan 27, 2022	Jan NEWA
>A>	AP	MEITHEAL	10MG/ML	A212803	001	Jan 27, 2022	Mar CAHN

TABLET;ORAL

FUROSEMIDE

>A>		@ EPIC PHARMA LLC	40MG	N018750	002	Jul 30, 1984	Mar CAHN
>D>		@ SANDOZ	40MG	N018750	002	Jul 30, 1984	Mar CAHN

GABAPENTIN

CAPSULE;ORAL

NEURONTIN

	AB	+ VIATRIS	100MG	N020235	001	Dec 30, 1993	Feb CAHN
	AB	+	300MG	N020235	002	Dec 30, 1993	Feb CAHN
	AB	+!	400MG	N020235	003	Dec 30, 1993	Feb CAHN

	SOLUTION;ORAL							
	GABAPENTIN							
	@ PAI HOLDINGS PHARM	250MG/5ML	A211330	001	Dec 03, 2019	Feb	CAHN	
	@ VISTAPHARM	250MG/5ML	A211330	001	Dec 03, 2019	Feb	CAHN	
	NEURONTIN							
AA	+! VIATRIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb	CAHN	
	TABLET;ORAL							
	NEURONTIN							
AB	+ VIATRIS	600MG	N020882	001	Oct 09, 1998	Feb	CAHN	
AB	+!	800MG	N020882	002	Oct 09, 1998	Feb	CAHN	
	<u>GABAPENTIN ENACARBIL</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	HORIZANT							
>D>	+ ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011	Mar	CAHN	
>D>	+!	600MG	N022399	001	Apr 06, 2011	Mar	CAHN	
>A>	+ AZURITY	300MG	N022399	002	Dec 13, 2011	Mar	CAHN	
>A>	+!	600MG	N022399	001	Apr 06, 2011	Mar	CAHN	
	<u>GALLIUM GA-68 GOZETOTIDE</u>							
	POWDER;INTRAVENOUS							
	ILLUCCIX							
>A>	+! TELIX	N/A	N214032	001	Dec 17, 2021	Mar	CPOT	
>D>	+!	6.7mCi/ML	N214032	001	Dec 17, 2021	Mar	CPOT	
>A>	LOCAMETZ							
>A>	+! AAA USA NOVARTIS	N/A	N215841	001	Mar 23, 2022	Mar	NEWA	
	<u>GANCICLOVIR SODIUM</u>							
	INJECTABLE;INJECTION							
	GANCICLOVIR SODIUM							
	@ STERISCIENCE	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Feb	CAHN	
	<u>GEMFIBROZIL</u>							
	TABLET;ORAL							
	GEMFIBROZIL							
	@ CHARTWELL RX	600MG	A074615	001	Sep 29, 1995	Feb	CAHN	
	<u>GEMIFLOXACIN MESYLATE</u>							
	TABLET;ORAL							
	FACTIVE							
	+ @ LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jan	DISC	
	GEMIFLOXACIN MESYLATE							
	@ ORBION PHARMS	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jan	DISC	
	<u>GLIPIZIDE</u>							
	TABLET;ORAL							
	GLIPIZIDE							
AB	AUROBINDO PHARMA USA	5MG	A074226	001	May 10, 1994	Feb	CAHN	
AB		10MG	A074226	002	May 10, 1994	Feb	CAHN	
	<u>GLYBURIDE</u>							
	TABLET;ORAL							
	GLYBURIDE							
>D>	AB1 SUNNY	1.25MG	A203581	001	Apr 14, 2016	Mar	DISC	
>A>	@	1.25MG	A203581	001	Apr 14, 2016	Mar	DISC	
>D>	AB1	2.5MG	A203581	002	Apr 14, 2016	Mar	DISC	
>A>	@	2.5MG	A203581	002	Apr 14, 2016	Mar	DISC	
>D>	AB1	5MG	A203581	003	Apr 14, 2016	Mar	DISC	
>A>	@	5MG	A203581	003	Apr 14, 2016	Mar	DISC	
	GLYBURIDE (MICRONIZED)							
	@ CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998	Feb	CAHN	
	@	3MG	A075174	002	Jun 22, 1998	Feb	CAHN	
	<u>GRANISETRON HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	GRANISETRON HYDROCHLORIDE							
>D>	AP WOCKHARDT USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078566	001	Feb 29, 2008	Mar	DISC	
>A>	@	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078566	001	Feb 29, 2008	Mar	DISC	
	@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078564	001	Jun 30, 2008	Feb	DISC	
>D>	AP	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078565	001	Jun 30, 2008	Mar	DISC	

INJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

>A> @ EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078565 001 Jun 30, 2008 Mar DISC

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

>A> AB SANDOZ 0.5MG A071209 002 Nov 17, 1986 Mar CMS1
>A> AB 1MG A071209 003 Nov 17, 1986 Mar CMS1
>A> @ 2MG A071209 004 Nov 17, 1986 Mar CMS1

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP +! B BRAUN 4,000 UNITS/100ML N019952 001 Jul 20, 1992 Mar CTEC
>A> +! 4,000 UNITS/100ML N019952 001 Jul 20, 1992 Mar CTEC
>D> AP HOSPIRA 4,000 UNITS/100ML N019805 001 Jan 25, 1989 Mar DISC
>A> @ 4,000 UNITS/100ML N019805 001 Jan 25, 1989 Mar DISC

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP HOSPIRA 5,000 UNITS/100ML N019805 002 Jan 25, 1989 Mar DISC
>A> @ 5,000 UNITS/100ML N019805 002 Jan 25, 1989 Mar DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL
BIDIL

>D> +! ARBOR PHARMS LLC 37.5MG;20MG N020727 001 Jun 23, 2005 Mar CFTG
>A> AB +! AZURITY 37.5MG;20MG N020727 001 Jun 23, 2005 Mar CFTG
>A> ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE
>A> AB RICONPHARMA LLC 37.5MG;20MG A215586 001 Apr 06, 2022 Mar NFTG

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

@ CHARTWELL RX 25MG A087565 001 Mar 09, 1982 Feb CAHN
@ 50MG A084912 001 Feb CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ CHARTWELL RX 25MG;40MG A071060 001 Aug 26, 1987 Feb CAHN
@ 25MG;80MG A071061 001 Aug 26, 1987 Jan CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL
MAXZIDE

AB +! AUROBINDO PHARMA USA 50MG;75MG N019129 001 Oct 22, 1984 Feb CAHN
MAXZIDE-25
AB + AUROBINDO PHARMA USA 25MG;37.5MG N019129 003 May 13, 1988 Feb CAHN
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB RUBICON 25MG;37.5MG A216211 001 Feb 23, 2022 Feb NEWA
AB 50MG;75MG A216211 002 Feb 23, 2022 Feb NEWA

HYDROXOCOBALAMIN

INJECTABLE; INJECTION
CYANOKIT

>A> @ BTG INTL 2.5GM/VIAL (5GM/KIT) N022041 002 Dec 15, 2006 Mar CAHN
>A> +! 5GM/VIAL (5GM/KIT) N022041 001 Apr 08, 2011 Mar CAHN
>D> @ SERB SA 2.5GM/VIAL (5GM/KIT) N022041 002 Dec 15, 2006 Mar CAHN
>D> +! 5GM/VIAL (5GM/KIT) N022041 001 Apr 08, 2011 Mar CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

! ACCORD HLTHCARE 400MG A213342 004 Aug 18, 2021 Jan CHRS
! 400MG A213342 004 Aug 18, 2021 Jan CHRS
+ NOVITIUM PHARMA 200MG N214581 001 Jan 14, 2022 Jan NEWA
+! 300MG N214581 002 Jan 14, 2022 Jan NEWA

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

@ PAI HOLDINGS PHARM	10MG/5ML	A 040391	001	Apr 10, 2002	Jan	CAHN
----------------------	----------	----------	-----	--------------	-----	------

IBUPROFEN

TABLET;ORAL

IBUPROFEN

>D>	@ HEC PHARM	400MG	A 204062	001	Sep 10, 2018	Mar	CAHN
>D>	@	600MG	A 204062	002	Sep 10, 2018	Mar	CAHN
>D>	@	800MG	A 204062	003	Sep 10, 2018	Mar	CAHN
>A>	@ SUNSHINE	400MG	A 204062	001	Sep 10, 2018	Mar	CAHN
>A>	@	600MG	A 204062	002	Sep 10, 2018	Mar	CAHN
>A>	@	800MG	A 204062	003	Sep 10, 2018	Mar	CAHN
>A> AB	YICHANG HUMANWELL	400MG	A 215318	001	Mar 30, 2022	Mar	NEWA
>A> AB		600MG	A 215318	002	Mar 30, 2022	Mar	NEWA
>A> AB		800MG	A 215318	003	Mar 30, 2022	Mar	NEWA

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

@ CHARTWELL RX	1.25MG	A 074594	001	May 23, 1996	Feb	CAHN
@	2.5MG	A 074594	002	May 23, 1996	Feb	CAHN

IOFLUPANE I-123

SOLUTION;INTRAVENOUS

DATSCAN

>D>	+! GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N 022454	001	Jan 14, 2011	Mar	CFTG
>A> AP	+!	5mCi/2.5ML (2mCi/ML)	N 022454	001	Jan 14, 2011	Mar	CFTG
>A>	IOFLUPANE I-123						
>A> AP	CURIUM	5mCi/2.5ML (2mCi/ML)	A 213792	001	Mar 30, 2022	Mar	NFTG

ISONIAZID

SYRUP;ORAL

ISONIAZID

>D>	@ ANDA REPOSITORY	50MG/5ML	A 081118	001	Jul 21, 1997	Mar	CAHN
>A>	@ CHARTWELL RX	50MG/5ML	A 081118	001	Jul 21, 1997	Mar	CAHN

TABLET;ORAL

ISONIAZID

>D> AA	ANDA REPOSITORY	100MG	A 040090	001	Jun 26, 1997	Mar	CAHN
>D> AA		300MG	A 040090	002	Jun 26, 1997	Mar	CAHN
>A> AA	MIKART	100MG	A 040090	001	Jun 26, 1997	Mar	CAHN
>A> AA		300MG	A 040090	002	Jun 26, 1997	Mar	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

>D> AB	NESHER PHARMS	30MG	A 075395	001	Mar 16, 2000	Mar	CAHN
>D> AB		60MG	A 075395	002	Mar 16, 2000	Mar	CAHN
>D> AB		120MG	A 075395	003	Mar 16, 2000	Mar	CAHN
>A> AB	ZYDUS PHARMS	30MG	A 075395	001	Mar 16, 2000	Mar	CAHN
>A> AB		60MG	A 075395	002	Mar 16, 2000	Mar	CAHN
>A> AB		120MG	A 075395	003	Mar 16, 2000	Mar	CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

+ AMGEN INC	EQ 5MG BASE	N 206143	001	Apr 15, 2015	Jan	CTEC
+!	EQ 7.5MG BASE	N 206143	002	Apr 15, 2015	Jan	CTEC
	IVABRADINE HYDROCHLORIDE					
@ CENTAUR PHARMS PVT	EQ 5MG BASE	A 214051	001	Dec 30, 2021	Jan	DISC
@	EQ 7.5MG BASE	A 214051	002	Dec 30, 2021	Jan	DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

@ STERISCIENCE	15MG/ML	A 078299	001	Jul 16, 2007	Feb	CAHN
@	15MG/ML	A 201155	001	Aug 04, 2014	Feb	CAHN
@	30MG/ML	A 078299	002	Jul 16, 2007	Feb	CAHN
@	30MG/ML	A 201155	002	Aug 04, 2014	Feb	CAHN

TABLET;ORAL							
KETOROLAC TROMETHAMINE							
>A>	AB	SENORES PHARMS	10MG	A215788	001	Mar 23, 2022	Mar CAHN
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE</u>							
SOLUTION;IRRIGATION							
OMIDRIA							
AT	+	RAYNER SURGICAL	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Feb CAHN
<u>KETOTIFEN FUMARATE</u>							
DRUG-ELUTING CONTACT LENS;OPHTHALMIC							
ACUVUE THERAVISION WITH KETOTIFEN							
+	!	JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022	Feb NEWA
<u>LABETALOL HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
LABETALOL HYDROCHLORIDE							
		@ STERISCIENCE	5MG/ML	A079134	001	Feb 03, 2010	Feb CAHN
<u>LACOSAMIDE</u>							
TABLET;ORAL							
LACOSAMIDE							
>D>	AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016	Mar NFTG
>A>	AB		50MG	A204974	001	Mar 17, 2022	Mar NFTG
>D>	AB		100MG	A204974	002	Apr 28, 2016	Mar NFTG
>A>	AB		100MG	A204974	002	Mar 17, 2022	Mar NFTG
>D>	AB		150MG	A204974	003	Apr 28, 2016	Mar NFTG
>A>	AB		150MG	A204974	003	Mar 17, 2022	Mar NFTG
>D>	AB		200MG	A204974	004	Apr 28, 2016	Mar NFTG
>A>	AB		200MG	A204974	004	Mar 17, 2022	Mar NFTG
>A>	AB	ALKEM LABS LTD	50MG	A214695	001	Mar 31, 2022	Mar NEWA
>A>	AB		100MG	A214695	002	Mar 31, 2022	Mar NEWA
>A>	AB		150MG	A214695	003	Mar 31, 2022	Mar NEWA
>A>	AB		200MG	A214695	004	Mar 31, 2022	Mar NEWA
>D>	AB	AMNEAL PHARMS	50MG	A204857	001	Sep 09, 2016	Mar NFTG
>A>	AB		50MG	A204857	001	Mar 17, 2022	Mar NFTG
>D>	AB		100MG	A204857	002	Sep 09, 2016	Mar NFTG
>A>	AB		100MG	A204857	002	Mar 17, 2022	Mar NFTG
>D>	AB		150MG	A204857	003	Sep 09, 2016	Mar NFTG
>A>	AB		150MG	A204857	003	Mar 17, 2022	Mar NFTG
>D>	AB		200MG	A204857	004	Sep 09, 2016	Mar NFTG
>A>	AB		200MG	A204857	004	Mar 17, 2022	Mar NFTG
>A>	AB	GLENMARK PHARMS LTD	50MG	A205006	001	Mar 17, 2022	Mar NFTG
>A>	AB		100MG	A205006	002	Mar 17, 2022	Mar NFTG
>A>	AB		150MG	A205006	003	Mar 17, 2022	Mar NFTG
>A>	AB		200MG	A205006	004	Mar 17, 2022	Mar NFTG
>A>	AB	HETERO LABS LTD V	50MG	A204787	001	Mar 17, 2022	Mar NFTG
>A>	AB		100MG	A204787	002	Mar 17, 2022	Mar NFTG
>A>	AB		150MG	A204787	003	Mar 17, 2022	Mar NFTG
>A>	AB		200MG	A204787	004	Mar 17, 2022	Mar NFTG
>A>	AB	INDOCO	50MG	A208308	001	Mar 17, 2022	Mar NFTG
>A>	AB		100MG	A208308	002	Mar 17, 2022	Mar NFTG
>A>	AB		150MG	A208308	003	Mar 17, 2022	Mar NFTG
>A>	AB		200MG	A208308	004	Mar 17, 2022	Mar NFTG
>D>	AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016	Mar NFTG
>A>	AB		50MG	A204921	001	Mar 17, 2022	Mar NFTG
>D>	AB		100MG	A204921	002	Apr 28, 2016	Mar NFTG
>A>	AB		100MG	A204921	002	Mar 17, 2022	Mar NFTG
>D>	AB		150MG	A204921	003	Apr 28, 2016	Mar NFTG
>A>	AB		150MG	A204921	003	Mar 17, 2022	Mar NFTG
>D>	AB		200MG	A204921	004	Apr 28, 2016	Mar NFTG
>A>	AB		200MG	A204921	004	Mar 17, 2022	Mar NFTG
>A>	AB	SCIEGEN PHARMS INC	50MG	A205237	001	Mar 17, 2022	Mar NFTG
>A>	AB		100MG	A205237	002	Mar 17, 2022	Mar NFTG
>A>	AB		150MG	A205237	003	Mar 17, 2022	Mar NFTG
>A>	AB		200MG	A205237	004	Mar 17, 2022	Mar NFTG
>A>	AB	SUN PHARM	50MG	A205031	001	Mar 17, 2022	Mar NFTG
>A>	AB		100MG	A205031	002	Mar 17, 2022	Mar NFTG
>A>	AB		150MG	A205031	003	Mar 17, 2022	Mar NFTG
>A>	AB		200MG	A205031	004	Mar 17, 2022	Mar NFTG
>D>	AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Mar NFTG
>D>	AB		100MG	A205031	002	Apr 28, 2016	Mar NFTG
>D>	AB		150MG	A205031	003	Apr 28, 2016	Mar NFTG

TABLET;ORAL
LACOSAMIDE

>D>	AB		200MG	A205031	004	Apr 28, 2016	Mar	NFTG
		VIMPAT						
>D>	+	UCB INC	50MG	N022253	001	Oct 28, 2008	Mar	CFTG
>A>	AB	+	50MG	N022253	001	Oct 28, 2008	Mar	CFTG
>D>		+	100MG	N022253	002	Oct 28, 2008	Mar	CFTG
>A>	AB	+	100MG	N022253	002	Oct 28, 2008	Mar	CFTG
>D>		+	150MG	N022253	003	Oct 28, 2008	Mar	CFTG
>A>	AB	+	150MG	N022253	003	Oct 28, 2008	Mar	CFTG
>D>		+	200MG	N022253	004	Oct 28, 2008	Mar	CFTG
>A>	AB	+	200MG	N022253	004	Oct 28, 2008	Mar	CFTG

LAMIVUDINE

TABLET;ORAL
LAMIVUDINE

>D>	AB	AUROBINDO PHARMA LTD	150MG	A202032	001	Nov 17, 2011	Mar	DISC
>A>		@	150MG	A202032	001	Nov 17, 2011	Mar	DISC
>D>	AB		300MG	A202032	002	Nov 17, 2011	Mar	DISC
>A>		@	300MG	A202032	002	Nov 17, 2011	Mar	DISC

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL
LAMIVUDINE AND ZIDOVUDINE

>A>		@ CHARTWELL RX	150MG;300MG	A079081	001	May 25, 2011	Mar	CAHN
>D>		@ TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011	Mar	CAHN

LAMOTRIGINE

TABLET, FOR SUSPENSION;ORAL
LAMICTAL CD

AB	+	GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000	Jan	CDFR
AB	+		5MG	N020764	001	Aug 24, 1998	Jan	CDFR
AB	+		25MG	N020764	002	Aug 24, 1998	Jan	CDFR
		@	100MG	N020764	003	Aug 24, 1998	Jan	CDFR
		LAMOTRIGINE						
AB		ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	Jan	CDFR
AB			25MG	A201168	002	Jun 12, 2014	Jan	CDFR
AB		AUROBINDO PHARMA	5MG	A090401	002	Nov 04, 2009	Jan	CDFR
AB			25MG	A090401	003	Nov 04, 2009	Jan	CDFR
AB		DR REDDYS LABS LTD	5MG	A076701	001	Jan 22, 2009	Jan	CDFR
AB			25MG	A076701	002	Jan 22, 2009	Jan	CDFR
AB		GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	Jan	CDFR
AB			25MG	A079099	002	Feb 19, 2009	Jan	CDFR
		@ JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jan	CDFR
		@	25MG	A200220	002	Feb 28, 2011	Jan	CDFR
		@ MYLAN	5MG	A076630	001	Jan 22, 2009	Jan	CDFR
		@	25MG	A076630	002	Jan 22, 2009	Jan	CDFR
		@ SANDOZ	5MG	A078409	002	Jan 22, 2009	Jan	CDFR
		@	25MG	A078409	003	Jan 22, 2009	Jan	CDFR
AB		TARO	5MG	A079204	001	Feb 04, 2009	Jan	CDFR
AB			25MG	A079204	002	Feb 04, 2009	Jan	CDFR
		@ TEVA	5MG	A076420	001	Jun 21, 2006	Jan	CDFR
		@	25MG	A076420	002	Jun 21, 2006	Jan	CDFR
AB		WATSON LABS	2MG	A076928	001	Jan 22, 2009	Jan	CDFR
AB			5MG	A076928	002	Jan 22, 2009	Jan	CDFR
AB			25MG	A076928	003	Jan 22, 2009	Jan	CDFR
AB		ZYDUS PHARMS USA INC	5MG	A078009	002	Jan 22, 2009	Jan	CDFR
AB			25MG	A078009	003	Jan 22, 2009	Jan	CDFR

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB		AMRING PHARMS	25MG	A214124	001	Feb 03, 2022	Jan	NEWA
AB			50MG	A214124	002	Feb 03, 2022	Jan	NEWA
AB			100MG	A214124	003	Feb 03, 2022	Jan	NEWA
AB			200MG	A214124	004	Feb 03, 2022	Jan	NEWA

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL
LANTHANUM CARBONATE

AB		BARR	EQ 500MG BASE	A090977	001	Jan 27, 2022	Jan	NEWA
AB			EQ 750MG BASE	A090977	002	Jan 27, 2022	Jan	NEWA
AB			EQ 1GM BASE	A090977	003	Jan 27, 2022	Jan	NEWA
AB		INVAGEN PHARMS	EQ 500MG BASE	A206868	001	Jan 24, 2022	Jan	NEWA
AB			EQ 750MG BASE	A206868	002	Jan 24, 2022	Jan	NEWA

	TABLET, CHEWABLE;ORAL LANTHANUM CARBONATE							
AB		EQ 1GM BASE	A206868	003	Jan 24, 2022	Jan	NEWA	
	<u>LEFLUNOMIDE</u>							
	TABLET;ORAL LEFLUNOMIDE							
AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jan	CMFD	
AB		20MG	A213497	002	May 10, 2021	Jan	CMFD	
	<u>LEUPROLIDE MESYLATE</u>							
	EMULSION;SUBCUTANEOUS CAMCEVI KIT							
	+! ACCORD	EQ 42MG BASE	N211488	001	May 25, 2021	Jan	CAHN	
	<u>LEVETIRACETAM</u>							
	INJECTABLE;INTRAVENOUS LEVETIRACETAM							
>A>	AP	PRINSTON INC	500MG/5ML (100MG/ML)	A209474	001	Mar 28, 2022	Mar	NEWA
	TABLET;ORAL LEVETIRACETAM							
	@	SECAN PHARMS	500MG	A205102	004	Dec 16, 2015	Jan	DISC
	@		1GM	A205102	003	Dec 16, 2015	Jan	DISC
>A>	AB	STALLION LABS	250MG	A079042	001	Jan 15, 2009	Mar	CAHN
>A>	AB		500MG	A079042	002	Jan 15, 2009	Mar	CAHN
>A>	AB		750MG	A079042	003	Jan 15, 2009	Mar	CAHN
>A>	AB		1GM	A079042	004	Jan 15, 2009	Mar	CAHN
>D>	AB	WOCKHARDT	250MG	A079042	001	Jan 15, 2009	Mar	CAHN
>D>	AB		500MG	A079042	002	Jan 15, 2009	Mar	CAHN
>D>	AB		750MG	A079042	003	Jan 15, 2009	Mar	CAHN
>D>	AB		1GM	A079042	004	Jan 15, 2009	Mar	CAHN
	<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>							
	SOLUTION;ORAL XYZAL							
	+ @	CHATTEM SANOFI	2.5MG/5ML	N022157	001	Jan 28, 2008	Jan	CAHN
	TABLET;ORAL XYZAL							
	+ @	CHATTEM SANOFI	5MG	N022064	001	May 25, 2007	Jan	CAHN
	<u>LEVOFLOXACIN</u>							
	TABLET;ORAL LEVOFLOXACIN							
>A>	AB	CHARTWELL MOLECULAR	250MG	A076890	001	Mar 30, 2012	Mar	CAHN
>A>	AB		500MG	A076890	002	Mar 30, 2012	Mar	CAHN
>A>	AB		750MG	A076890	003	Mar 30, 2012	Mar	CAHN
>D>	AB	CIPLA LTD	250MG	A076890	001	Mar 30, 2012	Mar	CAHN
>D>	AB		500MG	A076890	002	Mar 30, 2012	Mar	CAHN
>D>	AB		750MG	A076890	003	Mar 30, 2012	Mar	CAHN
	<u>LEVOLEUCOVORIN CALCIUM</u>							
	SOLUTION;INTRAVENOUS LEVOLEUCOVORIN CALCIUM							
	@	PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Feb	DISC
	<u>LEVOTHYROXINE SODIUM</u>							
	CAPSULE;ORAL LEVOTHYROXINE SODIUM							
	@	TEVA PHARMS USA INC	0.112MG	A211369	003	Apr 16, 2021	Jan	DISC
		TIROSINT						
	+	INSTITUT BIOCHIMIQUE	0.112MG	N021924	008	Oct 02, 2009	Jan	CTEC
	<u>LEVOTHYROXINE SODIUM **</u>							
	**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium							
	TABLET;ORAL LEVOLET							
AB1, AB3, AB4	GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003	Jan	CMFD	
AB1, AB3,		0.05MG	N021137	002	Jun 06, 2003	Jan	CMFD	

TABLET;ORAL
LEVOLET

AB4							
AB1,	0.075MG		N021137	003	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							
AB1,	0.088MG		N021137	004	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							
AB1,	0.1MG		N021137	005	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							
AB1,	0.112MG		N021137	006	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							
AB1,	0.125MG		N021137	007	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							
AB1,	0.137MG		N021137	008	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							
AB1,	0.15MG		N021137	009	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							
AB1,	0.175MG		N021137	010	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							
AB1,	0.2MG		N021137	011	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							
AB1,	0.3MG		N021137	012	Jun 06, 2003	Jan	CMFD
AB3,							
AB4							

LIDOCAINE HYDROCHLORIDE

SOLUTION;TOPICAL
LIDOCAINE HYDROCHLORIDE

>A> AT	NOVITIUM PHARMA	4%	A216250	001	Mar 23, 2022	Mar	NEWA
--------	-----------------	----	---------	-----	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL
LIDOCAINE AND PRILOCAINE
@ ACRUX DDS PTY

2.5%;2.5%

A212482	001	Jul 27, 2021	Jan	DISC
---------	-----	--------------	-----	------

LISINAPRIL

TABLET;ORAL
LISINAPRIL

@ STRIDES PHARMA	2.5MG
@	5MG
@	10MG
@	20MG
@	30MG
@	40MG

A076071	001	Jul 01, 2002	Jan	CAHN
A076071	002	Jul 01, 2002	Jan	CAHN
A076071	003	Jul 01, 2002	Jan	CAHN
A076071	004	Jul 01, 2002	Jan	CAHN
A076071	005	Jul 01, 2002	Jan	CAHN
A076071	006	Jul 01, 2002	Jan	CAHN

PRINIVIL

>D> AB	MERCK	5MG	N019558	001	Dec 29, 1987	Mar	DISC
>A>	@	5MG	N019558	001	Dec 29, 1987	Mar	DISC
>D> AB		40MG	N019558	004	Oct 25, 1988	Mar	DISC
>A>	@	40MG	N019558	004	Oct 25, 1988	Mar	DISC

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

>A>	@ CHARTWELL RX	2MG	A072993	001	Aug 28, 1992	Mar	CAHN
>D>	@ YAOPHARMA CO LTD	2MG	A072993	001	Aug 28, 1992	Mar	CAHN

LOPINAVIR; RITONAVIR

TABLET;ORAL
LOPINAVIR AND RITONAVIR

>A> AB	LAURUS	100MG;25MG	A213857	001	Mar 21, 2022	Mar	NEWA
>A> AB		200MG;50MG	A213857	002	Mar 21, 2022	Mar	NEWA

LORAZEPAMCAPSULE, EXTENDED RELEASE;ORAL
LOREEV XR

+ ALMATICA 1.5MG N214826 004 Feb 16, 2022 Feb NEWA

LUBIPROSTONECAPSULE;ORAL
LUBIPROSTONE

AB	DR REDDYS LABS LTD	8MCG	A206994	001	Feb 08, 2022	Jan NEWA
AB		24MCG	A206994	002	Feb 08, 2022	Jan NEWA
AB	TEVA PHARMS USA INC	8MCG	A209920	001	Jan 18, 2022	Jan NEWA
AB		24MCG	A209920	002	Jan 18, 2022	Jan NEWA

>A> LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN

>A> SOLUTION;INTRAVENOUS

>A> PLUVICTO

>A> +! AAA USA NOVARTIS 27mCi/ML N215833 001 Mar 23, 2022 Mar NEWA

MAFENIDE ACETATEFOR SOLUTION;TOPICAL
MAFENIDE ACETATE

AT	! PAR FORM	5%	A201511	001	Feb 12, 2013	Feb CHRS
	SULFAMYLOL					
	+ @ MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	Feb DISC

MARAVIROCTABLET;ORAL
MARAVIROC

AB	HETERO LABS LTD III	150MG	A203347	001	Feb 07, 2022	Jan NFTG
AB		300MG	A203347	002	Feb 07, 2022	Jan NFTG
	SELZENTRY					
AB	+ VIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007	Jan CFTG
AB	+!	300MG	N022128	002	Aug 06, 2007	Jan CFTG

MECLIZINE HYDROCHLORIDETABLET;ORAL
MECLIZINE HYDROCHLORIDE

AA	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Feb NEWA
AA		25MG	A200432	002	Feb 17, 2022	Feb NEWA
AA		50MG	A200432	003	Feb 17, 2022	Feb NEWA
	TABLET, CHEWABLE;ORAL					
	MECLIZINE HYDROCHLORIDE					
AA	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Feb NEWA

MELOXICAMCAPSULE;ORAL
VIVLODEX

>A>	+ @ ICEUTICA OPERATIONS	5MG	N207233	001	Oct 22, 2015	Mar CAHN
>A>	+ @	10MG	N207233	002	Oct 22, 2015	Mar CAHN
>D>	+ @ ZYLA	5MG	N207233	001	Oct 22, 2015	Mar CAHN
>D>	+ @	10MG	N207233	002	Oct 22, 2015	Mar CAHN

MEMANTINE HYDROCHLORIDETABLET;ORAL
MEMANTINE HYDROCHLORIDE

AB	ALLIED	5MG	A209527	001	May 07, 2018	Feb CAHN
AB		10MG	A209527	002	May 07, 2018	Feb CAHN
	@ RISING	5MG	A079225	001	Jan 30, 2015	Jan CAHN
	@	10MG	A079225	002	Jan 30, 2015	Jan CAHN

MEPERIDINE HYDROCHLORIDETABLET;ORAL
MEPERIDINE HYDROCHLORIDE

>D>	@ ANDA REPOSITORY	50MG	A040893	001	Jun 24, 2009	Mar CAHN
>D>	@	75MG	A040893	002	Jun 24, 2009	Mar CAHN
>D>	@	100MG	A040893	003	Jun 24, 2009	Mar CAHN
>D>	@	150MG	A040893	004	Jun 24, 2009	Mar CAHN
>A>	@ MIKART	50MG	A040893	001	Jun 24, 2009	Mar CAHN
>A>	@	75MG	A040893	002	Jun 24, 2009	Mar CAHN
>A>	@	100MG	A040893	003	Jun 24, 2009	Mar CAHN
>A>	@	150MG	A040893	004	Jun 24, 2009	Mar CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB1	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Feb CTEC
AB		750MG	A078596	002	Jan 03, 2008	Feb CTEC
	@ AMTA	500MG	A213394	001	Aug 03, 2021	Jan DISC
	@	1GM	A213394	002	Aug 03, 2021	Jan DISC
AB2	SCIEGEN PHARMS INC	500MG	A214629	001	Feb 22, 2022	Feb NEWA
AB2		1GM	A214629	002	Feb 22, 2022	Feb NEWA

METHADONE HYDROCHLORIDE

TABLET;ORAL

METHADONE HYDROCHLORIDE

	@ NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Feb DISC
	@	10MG	A210484	002	Aug 02, 2018	Feb DISC

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE LPF

+ @	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982	Jan CRLD
-----	---------	-----------------	---------	-----	--------------	----------

METHOTREXATE PRESERVATIVE FREE

+ @	HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005	Jan CRLD
+ @		EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005	Jan CRLD

METHOTREXATE SODIUM

+ @	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004		Jan CRLD
+ @		EQ 20MG BASE/VIAL	N011719	001		Jan CRLD
+ @		EQ 25MG BASE/ML	N011719	005		Jan CRLD
+ @		EQ 50MG BASE/VIAL	N011719	003		Jan CRLD
+ @		EQ 100MG BASE/VIAL	N011719	006		Jan CRLD

METHOTREXATE SODIUM PRESERVATIVE FREE

>D>	@ AUROMEDICS PHARMA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar CAHN
>D>	@	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar CAHN
>D>	@	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar CAHN
>D>	@	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar CAHN
>A>	@ EUGIA PHARMA SPECCLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar CAHN
>A>	@	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar CAHN
>A>	@	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar CAHN
>A>	@	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar CAHN
AP	HIKMA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Jan CHRS
	+ @ HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988	Jan CRLD
	MEXATE-AQ					
	+ @ BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985	Jan CRLD

METHYLPHENIDATE

FILM, EXTENDED RELEASE;TRANSDERMAL

DAYTRANA

>D>	+ NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006	Mar CFTG
>A> AB	+	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006	Mar CFTG
>D>	+	15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006	Mar CFTG
>A> AB	+	15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006	Mar CFTG
>D>	+	20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006	Mar CFTG
>A> AB	+	20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006	Mar CFTG
>D>	+!	30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006	Mar CFTG
>A> AB	+!	30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006	Mar CFTG

METHYLPHENIDATE

>A> AB	MYLAN TECH VIATRIS	10MG/9HR (1.1MG/HR)	A206497	001	Mar 14, 2022	Mar NFTG
>A> AB		15MG/9HR (1.6MG/HR)	A206497	002	Mar 14, 2022	Mar NFTG
>A> AB		20MG/9HR (2.2MG/HR)	A206497	003	Mar 14, 2022	Mar NFTG
>A> AB		30MG/9HR (3.3MG/HR)	A206497	004	Mar 14, 2022	Mar NFTG

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL	72MG	A 076655	002	Feb 28, 2022	Feb	NEWA
AB	! OSMOTICA	72MG	A 205327	005	Jul 28, 2017	Feb	CTEC

METHYLPREDNISOLONE

TABLET;ORAL
METHYLPREDNISOLONE

>D>	AB	AMNEAL	4MG	A 207481	001	Sep 21, 2021	Mar	DISC
>A>		@	4MG	A 207481	001	Sep 21, 2021	Mar	DISC
>D>	AB		8MG	A 207481	002	Sep 21, 2021	Mar	DISC
>A>		@	8MG	A 207481	002	Sep 21, 2021	Mar	DISC
>D>	AB		16MG	A 207481	003	Sep 21, 2021	Mar	DISC
>A>		@	16MG	A 207481	003	Sep 21, 2021	Mar	DISC
>D>	AB		32MG	A 207481	004	Sep 21, 2021	Mar	DISC
>A>		@	32MG	A 207481	004	Sep 21, 2021	Mar	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE ACETATE

AB	PAR STERILE PRODUCTS	40MG/ML	A 214297	001	Jan 21, 2022	Jan	NEWA
AB		80MG/ML	A 214297	002	Jan 21, 2022	Jan	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A 212396	001	Apr 20, 2021	Jan	CMFD
AP		EQ 125MG BASE/VIAL	A 212396	002	Apr 20, 2021	Jan	CMFD
AP		EQ 500MG BASE/VIAL	A 212396	003	Apr 20, 2021	Jan	CMFD
AP		EQ 1GM BASE/VIAL	A 212396	004	Apr 20, 2021	Jan	CMFD
AP		EQ 2GM BASE/VIAL	A 212396	005	Apr 20, 2021	Jan	CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL
METHYLTESTOSTERONE

AB	! IMPAX LABS INC	10MG	A 204851	001	Sep 21, 2015	Feb	CTEC
AB	NOVITIUM PHARMA	10MG	A 215270	001	Feb 18, 2022	Feb	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION
REGLAN

+ @ HIKMA EQ 5MG BASE/ML

N 017862 001 Jan CRLD

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A>	@	CHARTWELL RX	EQ 5MG BASE	A 074478	001	Oct 05, 1995	Mar	CAHN
>A>	@		EQ 10MG BASE	A 072215	001	Jan 30, 1990	Mar	CAHN
>A>	@		EQ 10MG BASE	A 074478	002	Oct 05, 1995	Mar	CAHN
>D>	@	YAOPHARMA CO LTD	EQ 5MG BASE	A 074478	001	Oct 05, 1995	Mar	CAHN
>D>	@		EQ 10MG BASE	A 072215	001	Jan 30, 1990	Mar	CAHN
>D>	@		EQ 10MG BASE	A 074478	002	Oct 05, 1995	Mar	CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

@ STERISCIENCE 1MG/ML

A 090317 001 Apr 19, 2010 Feb CAHN

TABLET;ORAL

METOPROLOL TARTRATE

>A>	@	CHARTWELL RX	50MG	A 073288	001	Mar 25, 1994	Mar	CAHN
>A>	@		100MG	A 073289	001	Mar 25, 1994	Mar	CAHN
>D>	@	YAOPHARMA CO LTD	50MG	A 073288	001	Mar 25, 1994	Mar	CAHN
>D>	@		100MG	A 073289	001	Mar 25, 1994	Mar	CAHN

METRONIDAZOLE

GEL;VAGINAL
METRONIDAZOLE

AB	GLENMARK PHARMS LTD	0.75%	A 215794	001	Jan 27, 2022	Jan	NEWA
----	---------------------	-------	----------	-----	--------------	-----	------

INJECTABLE;INJECTION
METRONIDAZOLE IN PLASTIC CONTAINER

@ RISING 500MG/100ML

A 205531 001 May 09, 2017 Jan CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@	STERISCIENCE	EQ 1MG BASE/ML	A 090315	001	Nov 29, 2010	Jan	CAHN
@		EQ 5MG BASE/ML	A 090315	002	Nov 29, 2010	Jan	CAHN

MIDOZALAM HYDROCHLORIDE

@	STERISCIENCE	EQ 1MG BASE/ML	A 090316	001	May 04, 2011	Feb	CAHN
@		EQ 5MG BASE/ML	A 090316	002	May 04, 2011	Feb	CAHN

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

AB	BRECKENRIDGE	100MG	A 209325	001	Feb 03, 2022	Jan	NEWA
----	--------------	-------	----------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL

AMZEEQ

+	JOURNEY	EQ 4% BASE	N 212379	001	Oct 18, 2019	Jan	CAHN
---	---------	------------	----------	-----	--------------	-----	------

ZILXI

+	JOURNEY	EQ 1.5% BASE	N 213690	001	May 28, 2020	Jan	CAHN
---	---------	--------------	----------	-----	--------------	-----	------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB	SQUARE PHARMS	15MG	A 205798	001	Jun 01, 2017	Jan	CAHN
AB		30MG	A 205798	002	Jun 01, 2017	Jan	CAHN
AB		45MG	A 205798	003	Jun 01, 2017	Jan	CAHN

MISOPROSTOL

TABLET; ORAL

CYTOTEC

>D>	+	PFIZER	0.1MG	N 019268	003	Sep 21, 1990	Mar	CTEC
>A>	AB	+	0.1MG	N 019268	003	Sep 21, 1990	Mar	CTEC
>D>	+	!	0.2MG	N 019268	001	Dec 27, 1988	Mar	CTEC
>A>	AB	+	0.2MG	N 019268	001	Dec 27, 1988	Mar	CTEC

MISOPROSTOL

>D>	@	ANI PHARMS	0.1MG	A 076095	001	Jul 10, 2002	Mar	CMFD
>A>	AB		0.1MG	A 076095	001	Jul 10, 2002	Mar	CMFD
>D>	@		0.2MG	A 076095	002	Jul 10, 2002	Mar	CMFD
>A>	AB		0.2MG	A 076095	002	Jul 10, 2002	Mar	CMFD

MITAPIVAT SULFATE

TABLET; ORAL

PYRUKYND

+	AGIOS PHARMS INC	EQ 5MG BASE	N 216196	001	Feb 17, 2022	Feb	NEWA
+		EQ 20MG BASE	N 216196	002	Feb 17, 2022	Feb	NEWA
+	!	EQ 50MG BASE	N 216196	003	Feb 17, 2022	Feb	NEWA

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED; NASAL

RYALTRIS

+	GLENMARK SPECIALTY	0.025MG/SPRAY; 0.665MG/SPRAY	N 211746	001	Jan 13, 2022	Jan	NEWA
---	--------------------	------------------------------	----------	-----	--------------	-----	------

MONTELUKAST SODIUM

GRANULE; ORAL

SINGULAIR

>D>	AB	+	MERCK	EQ 4MG BASE/PACKET	N 021409	001	Jul 26, 2002	Mar	CAHN
>A>	AB	+	ORGANON	EQ 4MG BASE/PACKET	N 021409	001	Jul 26, 2002	Mar	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

@	NORTEC DEV ASSOC	20MG	A 203158	001	Aug 04, 2021	Jan	DISC
@		30MG	A 203158	002	Aug 04, 2021	Jan	DISC
@		50MG	A 203158	003	Aug 04, 2021	Jan	DISC
@		60MG	A 203158	004	Aug 04, 2021	Jan	DISC
@		80MG	A 203158	005	Aug 04, 2021	Jan	DISC
@		100MG	A 203158	006	Aug 04, 2021	Jan	DISC

		INJECTABLE; INJECTION							
		MORPHINE SULFATE							
	+ @	HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021	Jan	DISC	
		INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021	Jan	CMFD	
		TABLET; ORAL							
		MORPHINE SULFATE							
	@	RICONPHARMA LLC	15MG	A215584	001	Feb 07, 2022	Feb	DISC	
AB			15MG	A215584	001	Feb 07, 2022	Jan	NEWA	
	@		30MG	A215584	002	Feb 07, 2022	Feb	DISC	
AB			30MG	A215584	002	Feb 07, 2022	Jan	NEWA	
		TABLET, EXTENDED RELEASE; ORAL							
		MORPHINE SULFATE							
>D>	AB	NESHER PHARMS	30MG	A076720	002	Dec 23, 2005	Mar	DISC	
>A>		@	30MG	A076720	002	Dec 23, 2005	Mar	DISC	
>D>	AB		60MG	A076720	001	May 19, 2004	Mar	DISC	
>A>		@	60MG	A076720	001	May 19, 2004	Mar	DISC	
		<u>MYCOPHENOLATE MOFETIL</u>							
		FOR SUSPENSION; ORAL							
		MYCOPHENOLATE MOFETIL							
AB		TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Jan	NEWA	
		<u>NAFCILLIN SODIUM</u>							
		INJECTABLE; INJECTION							
		NAFCILLIN SODIUM							
	@	STERISCIENCE	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Feb	CAHN	
	@		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Feb	CAHN	
		<u>NALMEFENE HYDROCHLORIDE</u>							
		INJECTABLE; INJECTION							
		REVEX							
	+ @	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan	CPOT	
	+ @		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan	CPOT	
		SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
		NALMEFENE HYDROCHLORIDE							
	!	PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jan	NEWA	
		REVEX							
	+ @	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan	CDFR	
	+ @		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan	CDFR	
		<u>NALOXONE HYDROCHLORIDE</u>							
		SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS							
		NALOXONE HYDROCHLORIDE (AUTOINJECTOR)							
	+!	KALEO INC	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	Feb	NEWA	
		<u>NEBIVOLOL HYDROCHLORIDE</u>							
		TABLET; ORAL							
		NEBIVOLOL HYDROCHLORIDE							
>A>	AB	AJANTA PHARMA LTD	EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Mar	NEWA	
>A>	AB		EQ 5MG BASE	A213349	002	Mar 31, 2022	Mar	NEWA	
>A>	AB		EQ 10MG BASE	A213349	003	Mar 31, 2022	Mar	NEWA	
>A>	AB		EQ 20MG BASE	A213349	004	Mar 31, 2022	Mar	NEWA	
>A>	AB	UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Mar	NEWA	
>A>	AB		EQ 5MG BASE	A213830	002	Mar 15, 2022	Mar	NEWA	
>A>	AB		EQ 10MG BASE	A213830	003	Mar 15, 2022	Mar	NEWA	
>A>	AB		EQ 20MG BASE	A213830	004	Mar 15, 2022	Mar	NEWA	
		<u>NIACIN</u>							
		TABLET, EXTENDED RELEASE; ORAL							
		NIACIN							
AB		MACLEODS PHARMS LTD	500MG	A204934	001	Mar 03, 2022	Feb	NEWA	
AB			1GM	A204934	002	Mar 03, 2022	Feb	NEWA	
		<u>NIFEDIPINE</u>							
		TABLET, EXTENDED RELEASE; ORAL							
		NIFEDIPINE							
>A>	AB2	ALKEM LABS LTD	30MG	A216067	001	Mar 29, 2022	Mar	NEWA	
>A>	AB2		60MG	A216067	002	Mar 29, 2022	Mar	NEWA	
>A>	AB2		90MG	A216067	003	Mar 29, 2022	Mar	NEWA	

NIMODIPINESOLUTION;ORAL
NYMALIZE

>D>	+ @	ARBOR PHARMS LLC	3MG/ML	N203340	001	May 10, 2013	Mar	CAHN
>D>	+	!	6MG/ML	N203340	002	Apr 08, 2020	Mar	CAHN
>A>	+ @	AZURITY	3MG/ML	N203340	001	May 10, 2013	Mar	CAHN
>A>	+	!	6MG/ML	N203340	002	Apr 08, 2020	Mar	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	INVENTIA	75MG;25MG	A211013	001	Feb 18, 2022	Feb	NEWA
----	----------	-----------	---------	-----	--------------	-----	------

NITROGLYCERINTABLET;SUBLINGUAL
NITROGLYCERIN

AB	ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022	Feb	NEWA	
AB		0.4MG	A210153	002	Mar 08, 2022	Feb	NEWA	
AB		0.6MG	A210153	003	Mar 08, 2022	Feb	NEWA	
	NITROSTAT							
AB	+ VIATRIS	0.3MG	N021134	001	May 01, 2000	Jan	CAHN	
AB	+	0.4MG	N021134	002	May 01, 2000	Jan	CAHN	
AB	+	!	0.6MG	N021134	003	May 01, 2000	Jan	CAHN

NORTRIPTYLINE HYDROCHLORIDECAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

	@ AUROBINDO PHARMA LTD	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb	CAHN
	@	EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb	CAHN
	@	EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb	CAHN
	@	EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb	CAHN

NYSTATINSUSPENSION;ORAL
NYSTATIN

AA	MEDLEY PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Feb	NEWA
----	---------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDEOINTMENT;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214186	001	Mar 04, 2022	Feb	NEWA
----	----------------------	-----------------------	---------	-----	--------------	-----	------

OCTREOTIDE ACETATECAPSULE, DELAYED RELEASE;ORAL
MYCAPSSA

	+	AMRYT	EQ 20MG BASE	N208232	001	Jun 26, 2020	Jan	CAHN
--	---	-------	--------------	---------	-----	--------------	-----	------

OFLOXACINSOLUTION/DROPS;OTIC
OFLOXACIN

AT	FDC LTD	0.3%	A215038	001	Jan 19, 2022	Jan	NEWA
----	---------	------	---------	-----	--------------	-----	------

OLANZAPINETABLET;ORAL
OLANZAPINE

>A>	AB	CHARTWELL MOLECULAR	2.5MG	A203333	001	Mar 15, 2016	Mar	CAHN
>A>	AB		5MG	A203333	002	Mar 15, 2016	Mar	CAHN
>A>	AB		7.5MG	A203333	003	Mar 15, 2016	Mar	CAHN
>A>	AB		10MG	A203333	004	Mar 15, 2016	Mar	CAHN
>A>	AB		15MG	A203333	005	Mar 15, 2016	Mar	CAHN
>A>	AB		20MG	A203333	006	Mar 15, 2016	Mar	CAHN
>D>	AB	INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Mar	CAHN
>D>	AB		5MG	A203333	002	Mar 15, 2016	Mar	CAHN
>D>	AB		7.5MG	A203333	003	Mar 15, 2016	Mar	CAHN
>D>	AB		10MG	A203333	004	Mar 15, 2016	Mar	CAHN
>D>	AB		15MG	A203333	005	Mar 15, 2016	Mar	CAHN
>D>	AB		20MG	A203333	006	Mar 15, 2016	Mar	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

>A>	AB	CHARTWELL MOLECULAR	5MG	A203456	001	Mar 16, 2016	Mar	CAHN
>A>	AB		10MG	A203456	002	Mar 16, 2016	Mar	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

>A>	AB		15MG	A203456	003	Mar 16, 2016	Mar	CAHN
>A>	AB		20MG	A203456	004	Mar 16, 2016	Mar	CAHN
>D>	AB	INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Mar	CAHN
>D>	AB		10MG	A203456	002	Mar 16, 2016	Mar	CAHN
>D>	AB		15MG	A203456	003	Mar 16, 2016	Mar	CAHN
>D>	AB		20MG	A203456	004	Mar 16, 2016	Mar	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

@	STRIDES PHARMA	10MG	A075876	001	May 29, 2003	Jan	CAHN
@		20MG	A075876	002	May 29, 2003	Jan	CAHN
@		40MG	A075876	003	Jan 21, 2009	Jan	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

>A>	AP	ATLANTIDE	EQ 2MG BASE/ML	A077577	001	Dec 26, 2006	Mar	CAHN
		@ STERISCIENCE	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Feb	CAHN
>D>	AP	WOCKHARDT	EQ 2MG BASE/ML	A077577	001	Dec 26, 2006	Mar	CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
>A>	AP	ATLANTIDE	EQ 2MG BASE/ML	A077716	001	Dec 26, 2006	Mar	CAHN
		@ STERISCIENCE	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Feb	CAHN
>D>	AP	WOCKHARDT	EQ 2MG BASE/ML	A077716	001	Dec 26, 2006	Mar	CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

		@ AUROBINDO PHARMA	EQ 24MG BASE	A078539	003	Jul 31, 2007	Feb	DISC
		@ CASI PHARMS INC	EQ 24MG BASE	A077517	003	Jun 25, 2007	Feb	DISC
>D>		DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006	Mar	DISC
>A>		@	EQ 16MG BASE	A076183	004	Dec 26, 2006	Mar	DISC
		@	EQ 24MG BASE	A076183	001	Dec 26, 2006	Feb	DISC
AB	!	GLENMARK GENERICS	EQ 8MG BASE	A077535	002	Jun 25, 2007	Feb	CHRS
		@	EQ 24MG BASE	A077535	003	Jun 25, 2007	Feb	DISC
		@ TEVA	EQ 4MG BASE	A076252	001	Jun 25, 2007	Feb	DISC
		@	EQ 8MG BASE	A076252	002	Jun 25, 2007	Feb	DISC
		@	EQ 24MG BASE	A076252	003	Jun 25, 2007	Feb	DISC
		ZOFRAN						
	+	@ NOVARTIS	EQ 4MG BASE	N020103	001	Dec 31, 1992	Feb	DISC
	+	@	EQ 8MG BASE	N020103	002	Dec 31, 1992	Feb	DISC
	+	@	EQ 24MG BASE	N020103	003	Aug 27, 1999	Feb	DISC

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

>D>	AB	APTAPHARMA INC	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021	Mar	DISC
>A>		@	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021	Mar	DISC
>A>	AB	HETERO LABS LTD V	EQ 6MG BASE/ML	A209590	001	Mar 28, 2022	Mar	NEWA
AB		LEADING PHARMA LLC	EQ 6MG BASE/ML	A214949	001	Feb 28, 2022	Feb	NEWA
AB		STRIDES PHARMA	EQ 6MG BASE/ML	A211894	001	Jan 13, 2022	Jan	NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

@	STERISCIENCE	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Feb	CAHN
@		EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Feb	CAHN

OXALIPLATIN

INJECTABLE; INTRAVENOUS
OXALIPLATIN

>A>		@ CHARTWELL MOLECULAR	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Mar	CAHN
>A>		@	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Mar	CAHN
>D>		@ CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Mar	CAHN
>D>		@	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Mar	CAHN

OXAZEPAM

CAPSULE;ORAL
SERAX

+	@	ALPHARMA US PHARMS	10MG	N015539	002		Jan	CRLD
+	@		15MG	N015539	004		Jan	CRLD
+	@		30MG	N015539	006		Jan	CRLD

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

>D>	@	ANDA REPOSITORY	5MG/5ML	A 075039	001	Jan 29, 1999	Mar	CAHN
>A>	@	CHARTWELL RX	5MG/5ML	A 075039	001	Jan 29, 1999	Mar	CAHN
>D>	AA	LANNETT CO INC	5MG/5ML	A 074520	001	Mar 29, 1996	Mar	CHRS
>A>	AA	!	5MG/5ML	A 074520	001	Mar 29, 1996	Mar	CHRS
>D>	AA	!	WOCKHARDT BIO AG	A 074868	001	Feb 12, 1997	Mar	DISC
>A>	@		5MG/5ML	A 074868	001	Feb 12, 1997	Mar	DISC

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

@ NOVEL LABS INC 100MG/5ML

A 204603 001 Apr 29, 2015 Feb DISC

TABLET;ORAL

ROXYBOND

>D>	@	PROTEGA PHARMS	5MG	N 209777	001	Apr 20, 2017	Mar	CMFD
>A>			5MG	N 209777	001	Apr 20, 2017	Mar	CMFD
	@		5MG	N 209777	001	Apr 20, 2017	Feb	CAHN
>D>	@		15MG	N 209777	002	Apr 20, 2017	Mar	CMFD
>A>			15MG	N 209777	002	Apr 20, 2017	Mar	CMFD
	@		15MG	N 209777	002	Apr 20, 2017	Feb	CAHN
>D>	@		30MG	N 209777	003	Apr 20, 2017	Mar	CMFD
>A>			30MG	N 209777	003	Apr 20, 2017	Mar	CMFD
	@		30MG	N 209777	003	Apr 20, 2017	Feb	CAHN

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

AP GLAND PHARMA LTD 6MG/ML

A 207326 001 Aug 23, 2016 Feb CTNA

PACRITINIB CITRATE

CAPSULE;ORAL

VONJO

+! CTI BIOPHARMA CORP EQ 100MG BASE

N 208712 001 Feb 28, 2022 Feb NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@ EMCURE PHARMS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

A 202951 001 Jun 29, 2021 Jan DISC

@ EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

A 202951 002 Jun 29, 2021 Jan DISC

PARICALCITOL

SOLUTION;INTRAVENOUS

PARICALCITOL

>D> AP RISING 0.002MG/ML (0.002MG/ML)

A 203897 001 Nov 02, 2017 Mar DISC

>A> @ 0.002MG/ML (0.002MG/ML)

A 203897 001 Nov 02, 2017 Mar DISC

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL

PAXIL

+ @ APOTEX EQ 10MG BASE

N 020885 001 Oct 09, 1998 Feb CAHN

+ @ EQ 20MG BASE

N 020885 002 Oct 09, 1998 Feb CAHN

+ @ EQ 30MG BASE

N 020885 003 Oct 09, 1998 Feb CAHN

+ @ EQ 40MG BASE

N 020885 004 Oct 09, 1998 Feb CAHN

SUSPENSION;ORAL

PAXIL

AB +! APOTEX EQ 10MG BASE/5ML

N 020710 001 Jun 25, 1997 Feb CAHN

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

>A> AB CHARTWELL RX EQ 10MG BASE

A 076618 001 Aug 15, 2005 Mar CAHN

>A> AB EQ 20MG BASE

A 076618 002 Aug 15, 2005 Mar CAHN

>A> AB EQ 30MG BASE

A 076618 003 Aug 15, 2005 Mar CAHN

>A> AB EQ 40MG BASE

A 076618 004 Aug 15, 2005 Mar CAHN

>D> AB TEVA EQ 10MG BASE

A 076618 001 Aug 15, 2005 Mar CAHN

>D> AB EQ 20MG BASE

A 076618 002 Aug 15, 2005 Mar CAHN

>D> AB EQ 30MG BASE

A 076618 003 Aug 15, 2005 Mar CAHN

>D> AB EQ 40MG BASE

A 076618 004 Aug 15, 2005 Mar CAHN

TABLET;ORAL

PAXIL

AB	+	APOTEX	EQ 10MG BASE	N020031	001	Dec 29, 1992	Feb CAHN
AB	+		EQ 20MG BASE	N020031	002	Dec 29, 1992	Feb CAHN
AB	+		EQ 30MG BASE	N020031	003	Dec 29, 1992	Feb CAHN
AB	+		EQ 40MG BASE	N020031	005	Dec 29, 1992	Feb CAHN
		@	EQ 50MG BASE	N020031	004	Dec 29, 1992	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

		@ SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan DISC
		@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan DISC

PAXIL CR

AB	+	APOTEX	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB	+		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB	+		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION

PENTAMIDINE ISETHIONATE

>A>	AP	XGEN PHARMS	300MG/VIAL	A206982	001	Mar 17, 2022	Mar NEWA
-----	----	-------------	------------	---------	-----	--------------	----------

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

>D>	AB	MYLAN	2MG	A206691	001	Apr 14, 2017	Mar DISC
>A>		@	2MG	A206691	001	Apr 14, 2017	Mar DISC
>D>	AB		4MG	A206691	002	Apr 14, 2017	Mar DISC
>A>		@	4MG	A206691	002	Apr 14, 2017	Mar DISC
>D>	AB		8MG	A206691	003	Apr 14, 2017	Mar DISC
>A>		@	8MG	A206691	003	Apr 14, 2017	Mar DISC
>D>	AB		16MG	A206691	004	Apr 14, 2017	Mar DISC
>A>		@	16MG	A206691	004	Apr 14, 2017	Mar DISC

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA	+	SANDOZ	30MG	A087190	001		Feb CRLD
----	---	--------	------	---------	-----	--	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1		ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Feb CMFD
AP1			50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Feb CMFD
AP1			100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Feb CMFD
		@ PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Jan DISC

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB	+	VIATRIS	125MG/5ML	N008762	001		Feb CAHN
		DILANTIN-30					
		@ VIATRIS	30MG/5ML	N008762	002		Feb CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

	+	VIATRIS	30MG EXTENDED	A084349	001		Feb CAHN
AB	+		100MG EXTENDED	A084349	002		Feb CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

@ STERISCIENCE

EQ 2GM BASE/VIAL;EQ 250MG

BASE/VIAL

A065458 001 Aug 15, 2014 Feb CAHN

@

EQ 3GM BASE/VIAL;EQ 375MG

BASE/VIAL

A065458 002 Aug 15, 2014 Feb CAHN

@

EQ 4GM BASE/VIAL;EQ 500MG

BASE/VIAL

A065458 003 Aug 15, 2014 Feb CAHN

PIRFENIDONE

CAPSULE;ORAL

PIRFENIDONE

AB	ACCORD HLTHCARE	267MG	A212731	001	Jan 20, 2022	Jan NEWA
	@ AMNEAL	267MG	A212569	001	Jan 03, 2022	Jan DISC

TABLET;ORAL

ESBRIET

AB	+ GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan CFTG
AB	+!	801MG	N208780	003	Jan 11, 2017	Jan CFTG

PIRFENIDONE

AB	ACCORD HLTHCARE	267MG	A212730	001	Jan 25, 2022	Jan NFTG
AB		801MG	A212730	002	Jan 25, 2022	Jan NFTG
>A>	AB AMNEAL	267MG	A212570	001	Mar 25, 2022	Mar NEWA
>A>	AB	801MG	A212570	002	Mar 25, 2022	Mar NEWA
AB	TEVA PHARMS USA	267MG	A212759	001	Jan 25, 2022	Jan NFTG
AB		801MG	A212759	002	Jan 25, 2022	Jan NFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@ NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A090019	001	May 27, 2009	Feb DISC
		.2GM/BOT				

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

	@ MYLAN	1MG	A210275	001	Jan 26, 2022	Feb CAHN
	@	1MG	A210275	001	Jan 26, 2022	Feb DISC
AB		1MG	A210275	001	Jan 26, 2022	Jan NEWA
	@	2MG	A210275	002	Jan 26, 2022	Feb CAHN
	@	2MG	A210275	002	Jan 26, 2022	Feb DISC
AB		2MG	A210275	002	Jan 26, 2022	Jan NEWA
	@	3MG	A210275	003	Jan 26, 2022	Feb CAHN
	@	3MG	A210275	003	Jan 26, 2022	Feb DISC
AB		3MG	A210275	003	Jan 26, 2022	Jan NEWA
	@	4MG	A210275	004	Jan 26, 2022	Feb CAHN
	@	4MG	A210275	004	Jan 26, 2022	Feb DISC
AB		4MG	A210275	004	Jan 26, 2022	Jan NEWA

POMALYST

	+ CELGENE	1MG	N204026	001	Feb 08, 2013	Feb CTEC
AB		1MG	N204026	001	Feb 08, 2013	Jan CTEC
		2MG	N204026	002	Feb 08, 2013	Feb CTEC
AB		2MG	N204026	002	Feb 08, 2013	Jan CTEC
		3MG	N204026	003	Feb 08, 2013	Feb CTEC
AB		3MG	N204026	003	Feb 08, 2013	Jan CTEC
		4MG	N204026	004	Feb 08, 2013	Feb CTEC
AB		4MG	N204026	004	Feb 08, 2013	Jan CTEC

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL

NOXAFIL POWDERMIX KIT

	+ @ MSD MERCK CO	300MG	N214770	001	May 31, 2021	Jan DISC
--	------------------	-------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

AB	BIOCON PHARMA	100MG	A214476	001	Feb 04, 2022	Jan NEWA
----	---------------	-------	---------	-----	--------------	----------

POTASSIUM ACETATE

INJECTABLE;INJECTION

POTASSIUM ACETATE

>D>	AP EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Mar DISC
>A>	@	2MEQ/ML	A212692	001	Oct 20, 2021	Mar DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

>D>	AB LANNETT CO INC	8MEQ	A204210	001	Mar 28, 2016	Mar DISC
>A>	@	8MEQ	A204210	001	Mar 28, 2016	Mar DISC
>D>	AB	10MEQ	A204210	002	Mar 28, 2016	Mar DISC
>A>	@	10MEQ	A204210	002	Mar 28, 2016	Mar DISC

		FOR SOLUTION;ORAL							
		POTASSIUM CHLORIDE							
	AA	GRANULES	20MEQ	A213467	001	Jan 27, 2022	Jan	NEWA	
>A>	AA	RUBICON	20MEQ	A214108	001	Mar 24, 2022	Mar	NEWA	
		INJECTABLE;INJECTION							
		POTASSIUM CHLORIDE							
>D>	AP	+ FRESENIUS KABI USA	2MEQ/ML	A080225	001		Mar	DISC	
>A>		+ @	2MEQ/ML	A080225	001		Mar	DISC	
		POTASSIUM CHLORIDE 10MEQ							
>D>		@ FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar	CMFD	
>A>	AP		14.9MG/ML	A211087	001	Sep 09, 2020	Mar	CMFD	
>D>		@	746MG/100ML	A211087	002	Sep 09, 2020	Mar	CMFD	
>A>	AP		746MG/100ML	A211087	002	Sep 09, 2020	Mar	CMFD	
		POTASSIUM CHLORIDE 20MEQ							
>D>		@ FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar	CMFD	
>A>	AP		29.8MG/ML	A211087	003	Sep 09, 2020	Mar	CMFD	
>D>		@	1.49GM/100ML	A211087	005	May 07, 2021	Mar	CMFD	
>A>	AP		1.49GM/100ML	A211087	005	May 07, 2021	Mar	CMFD	
		POTASSIUM CHLORIDE 40MEQ							
>D>		@ FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar	CMFD	
>A>	AP		2.98GM/100ML	A211087	004	Sep 09, 2020	Mar	CMFD	
		SOLUTION;ORAL							
		POTASSIUM CHLORIDE							
	AA	RUBICON	20MEQ/15ML	A214656	001	Jan 13, 2022	Jan	NEWA	
	AA		40MEQ/15ML	A214656	002	Jan 13, 2022	Jan	NEWA	
		TABLET, EXTENDED RELEASE;ORAL							
		K-TAB							
>D>	BC	+ ABBVIE	8MEQ	N018279	002	Aug 01, 1988	Mar	DISC	
>A>		+ @	8MEQ	N018279	002	Aug 01, 1988	Mar	DISC	
		<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>							
		TABLET;ORAL							
>D>		MIRAPEX							
>D>	AB	+ BOEHRINGER INGELHEIM	0.125MG	N020667	001	Jul 01, 1997	Mar	DISC	
>A>		+ @	0.125MG	N020667	001	Jul 01, 1997	Mar	DISC	
>D>	AB	+!	0.25MG	N020667	002	Jul 01, 1997	Mar	DISC	
>A>		+ @	0.25MG	N020667	002	Jul 01, 1997	Mar	DISC	
>D>	AB	+	0.5MG	N020667	006	Feb 12, 1998	Mar	DISC	
>A>		+ @	0.5MG	N020667	006	Feb 12, 1998	Mar	DISC	
>D>	AB	+	0.75MG	N020667	007	Jul 30, 2007	Mar	DISC	
>A>		+ @	0.75MG	N020667	007	Jul 30, 2007	Mar	DISC	
>D>	AB	+	1MG	N020667	003	Jul 01, 1997	Mar	DISC	
>A>		+ @	1MG	N020667	003	Jul 01, 1997	Mar	DISC	
>D>	AB	+	1.5MG	N020667	005	Jul 01, 1997	Mar	DISC	
>A>		+ @	1.5MG	N020667	005	Jul 01, 1997	Mar	DISC	
		PRAMIPEXOLE DIHYDROCHLORIDE							
>D>	AB	GLENMARK GENERICS	0.25MG	A090781	002	Oct 08, 2010	Mar	CHRS	
>A>	AB	!	0.25MG	A090781	002	Oct 08, 2010	Mar	CHRS	
		TABLET, EXTENDED RELEASE;ORAL							
		PRAMIPEXOLE DIHYDROCHLORIDE							
	AB	NOVAST LABS	0.375MG	A213444	001	Feb 03, 2022	Jan	NEWA	
	AB		0.75MG	A213444	002	Feb 03, 2022	Jan	NEWA	
	AB		1.5MG	A213444	003	Feb 03, 2022	Jan	NEWA	
	AB		2.25MG	A213444	004	Feb 03, 2022	Jan	NEWA	
	AB		3MG	A213444	005	Feb 03, 2022	Jan	NEWA	
	AB		3.75MG	A213444	006	Feb 03, 2022	Jan	NEWA	
	AB		4.5MG	A213444	007	Feb 03, 2022	Jan	NEWA	
		<u>PRAZOSIN HYDROCHLORIDE</u>							
		CAPSULE;ORAL							
		PRAZOSIN HYDROCHLORIDE							
		@ ANI PHARMS	EQ 5MG BASE	A072577	003	May 16, 1989	Feb	DISC	
		<u>PREDNISOLONE</u>							
		TABLET;ORAL							
		PREDNISOLONE							
>D>	!	WATSON LABS	5MG	A080354	001		Mar	CRLD	
>A>	+!		5MG	A080354	001		Mar	CRLD	

PREDNISONETABLET; ORAL
PREDNISONE

>A>	AB	AUROBINDO PHARMA LTD	2.5MG	A215672	001	Mar 28, 2022	Mar	NEWA
>A>	AB		5MG	A215672	002	Mar 28, 2022	Mar	NEWA
>A>	AB		10MG	A215672	003	Mar 28, 2022	Mar	NEWA
>A>	AB		20MG	A215672	004	Mar 28, 2022	Mar	NEWA
>A>	AB		50MG	A215672	005	Mar 28, 2022	Mar	NEWA

PREGABALINCAPSULE; ORAL
PREGABALIN

AB	ALLIED	50MG	A210585	001	Dec 26, 2019	Feb	CAHN
AB		75MG	A210585	002	Dec 26, 2019	Feb	CAHN
AB		100MG	A210585	003	Dec 26, 2019	Feb	CAHN
AB		150MG	A210585	004	Dec 26, 2019	Feb	CAHN
AB		200MG	A210585	005	Dec 26, 2019	Feb	CAHN
AB		300MG	A210585	006	Dec 26, 2019	Feb	CAHN
AB	ESKAYEF	25MG	A212988	001	Mar 08, 2022	Feb	NEWA
AB		50MG	A212988	002	Mar 08, 2022	Feb	NEWA
AB		75MG	A212988	003	Mar 08, 2022	Feb	NEWA
AB		100MG	A212988	004	Mar 08, 2022	Feb	NEWA
AB		150MG	A212988	005	Mar 08, 2022	Feb	NEWA
AB		200MG	A212988	006	Mar 08, 2022	Feb	NEWA
AB		225MG	A212988	007	Mar 08, 2022	Feb	NEWA
AB		300MG	A212988	008	Mar 08, 2022	Feb	NEWA

SOLUTION; ORAL

PREGABALIN

AA	INVATECH	20MG/ML	A212604	001	Feb 18, 2022	Feb	NEWA
----	----------	---------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

PREGABALIN

>D>	AB	MYLAN	82.5MG	A211948	001	Apr 13, 2021	Mar	DISC
>A>		@	82.5MG	A211948	001	Apr 13, 2021	Mar	DISC
>D>	AB		165MG	A211967	001	Nov 04, 2021	Mar	DISC
>A>		@	165MG	A211967	001	Nov 04, 2021	Mar	DISC
>A>	AB	RUBICON	82.5MG	A215249	001	Mar 22, 2022	Mar	NEWA
>A>	AB		165MG	A215249	002	Mar 22, 2022	Mar	NEWA
>A>	AB		330MG	A215249	003	Mar 22, 2022	Mar	NEWA

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

>A>		@ ATLANTIDE	25MG/ML	A040785	001	Sep 26, 2008	Mar	CAHN
>A>		@	50MG/ML	A040785	002	Sep 26, 2008	Mar	CAHN
>D>		@ WOCKHARDT	25MG/ML	A040785	001	Sep 26, 2008	Mar	CAHN
>D>		@	50MG/ML	A040785	002	Sep 26, 2008	Mar	CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

>D>		@ ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Mar	CAHN
		@	1MG/ML	A075792	001	Aug 29, 2000	Feb	DISC
>A>		@ CHARTWELL INJECTABLE	1MG/ML	A075792	001	Aug 29, 2000	Mar	CAHN
AP	!	HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008	Feb	CTEC

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

>A>		@ CHARTWELL RX	10MG	A070663	001	Jun 13, 1986	Mar	CAHN
>A>		@	20MG	A070664	001	Jun 13, 1986	Mar	CAHN
>A>		@	40MG	A070665	001	Jun 13, 1986	Mar	CAHN
>A>		@	60MG	A070666	001	Oct 10, 1986	Mar	CAHN
>A>		@	80MG	A070667	001	Jun 13, 1986	Mar	CAHN
>D>		@ YAOPHARMA CO LTD	10MG	A070663	001	Jun 13, 1986	Mar	CAHN
>D>		@	20MG	A070664	001	Jun 13, 1986	Mar	CAHN
>D>		@	40MG	A070665	001	Jun 13, 1986	Mar	CAHN
>D>		@	60MG	A070666	001	Oct 10, 1986	Mar	CAHN
>D>		@	80MG	A070667	001	Jun 13, 1986	Mar	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

>A>	@	CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Mar CAHN
>A>	@		EQ 10MG BASE	A076803	002	Mar 02, 2005	Mar CAHN
>A>	@		EQ 20MG BASE	A076803	003	Mar 02, 2005	Mar CAHN
>A>	@		EQ 40MG BASE	A076803	004	Mar 02, 2005	Mar CAHN
>D>	@	YAOPHARMA CO LTD	EQ 5MG BASE	A076803	001	Mar 02, 2005	Mar CAHN
>D>	@		EQ 10MG BASE	A076803	002	Mar 02, 2005	Mar CAHN
>D>	@		EQ 20MG BASE	A076803	003	Mar 02, 2005	Mar CAHN
>D>	@		EQ 40MG BASE	A076803	004	Mar 02, 2005	Mar CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

>D>	AB	EYWA	324MG	A212589	001	Sep 17, 2021	Mar DISC
>A>	@		324MG	A212589	001	Sep 17, 2021	Mar DISC
>D>	AB	! SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987	Mar CTEC
>A>	!		324MG	A089338	001	Feb 11, 1987	Mar CTEC

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

>A>	@	CHARTWELL RX	1.25MG	A077514	001	Jun 18, 2008	Mar CAHN
>A>	@		2.5MG	A077514	002	Jun 18, 2008	Mar CAHN
>A>	@		5MG	A077514	003	Jun 18, 2008	Mar CAHN
>A>	@		10MG	A077514	004	Jun 18, 2008	Mar CAHN
>D>	@	YAOPHARMA CO LTD	1.25MG	A077514	001	Jun 18, 2008	Mar CAHN
>D>	@		2.5MG	A077514	002	Jun 18, 2008	Mar CAHN
>D>	@		5MG	A077514	003	Jun 18, 2008	Mar CAHN
>D>	@		10MG	A077514	004	Jun 18, 2008	Mar CAHN

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

>A>	+	SPIL	500MG	N216018	001	Feb 28, 2022	Mar CAHN
>A>	+	!	1GM	N216018	002	Feb 28, 2022	Mar CAHN
>D>	+	SUN PHARMA GLOBAL	500MG	N216018	001	Feb 28, 2022	Mar CAHN
			500MG	N216018	001	Feb 28, 2022	Feb NEWA
>D>	+	!	1GM	N216018	002	Feb 28, 2022	Mar CAHN
			1GM	N216018	002	Feb 28, 2022	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		VKT PHARMA	500MG	A214035	001	Jan 19, 2022	Jan NEWA
AB			1GM	A214035	002	Jan 19, 2022	Jan NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@	DR REDDYS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Jan DISC
@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Jan DISC

RILUZOLE

SUSPENSION;ORAL

TIGLUTIK KIT

+	!	ITALFARMACO SPA	50MG/10ML	N209080	001	Sep 05, 2018	Jan CAHN
---	---	-----------------	-----------	---------	-----	--------------	----------

RITONAVIR

TABLET;ORAL

RITONAVIR

>A>	AB	CIPLA	100MG	A202573	001	Jan 15, 2015	Mar CAHN
>D>	AB	HIKMA	100MG	A202573	001	Jan 15, 2015	Mar CAHN

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB		ZYDUS PHARMS	500MCG	A208303	001	Feb 10, 2022	Feb NEWA
----	--	--------------	--------	---------	-----	--------------	----------

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

	@	STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jan	CAHN
	@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Jan	CAHN
	@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Jan	CAHN
	@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Jan	CAHN
>A>	@	ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	Mar	CAHN
>A>	@		EQ 10MG BASE	A206513	002	Mar 01, 2019	Mar	CAHN
>A>	@		EQ 20MG BASE	A206513	003	Mar 01, 2019	Mar	CAHN
>A>	@		EQ 40MG BASE	A206513	004	Mar 01, 2019	Mar	CAHN
>D>	@	ZYDUS PHARMS	EQ 5MG BASE	A206513	001	Mar 01, 2019	Mar	CAHN
>D>	@		EQ 10MG BASE	A206513	002	Mar 01, 2019	Mar	CAHN
>D>	@		EQ 20MG BASE	A206513	003	Mar 01, 2019	Mar	CAHN
>D>	@		EQ 40MG BASE	A206513	004	Mar 01, 2019	Mar	CAHN

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

	+ @	LANTHEUS MEDICAL	50mCi/ML	N020570	001	Mar 28, 1997	Jan	DISC
--	-----	------------------	----------	---------	-----	--------------	-----	------

SELINEXOR

TABLET; ORAL

XPOVIO

>D>	+	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019	Mar	CHRS
>A>	+		20MG	N212306	001	Jul 03, 2019	Mar	CHRS
>D>	+		60MG	N212306	004	Apr 15, 2021	Mar	CHRS
>A>	+		60MG	N212306	004	Apr 15, 2021	Mar	CHRS

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

ZOLOFT

AA	+	VIATRIS	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jan	CAHN
----	---	---------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

ZOLOFT

AB	+	VIATRIS	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jan	CAHN
AB	+		EQ 50MG BASE	N019839	001	Dec 30, 1991	Jan	CAHN
AB	+		EQ 100MG BASE	N019839	002	Dec 30, 1991	Jan	CAHN
	+ @		EQ 150MG BASE	N019839	003	Dec 30, 1991	Jan	CAHN
	+ @		EQ 200MG BASE	N019839	004	Dec 30, 1991	Jan	CAHN

SEVELAMER CARBONATE

TABLET; ORAL

SEVELAMER CARBONATE

AB		MICRO LABS	800MG	A215537	001	Feb 07, 2022	Jan	NEWA
	@	STRIDES PHARMA	800MG	A201069	001	Aug 05, 2020	Jan	CAHN

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

AB	+	VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Feb	CAHN
----	---	---------	-----------------	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

>A>	AB	LUPIN LTD	EQ 10MG BASE/ML	A211638	001	Mar 23, 2022	Mar	NEWA
	AB	MSN	EQ 10MG BASE/ML	A214641	001	Feb 08, 2022	Jan	NEWA

SOLUTION; INTRAVENOUS

REVATIO

AP	+	VIATRIS	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Feb	CAHN
----	---	---------	--	---------	-----	--------------	-----	------

TABLET; ORAL

REVATIO

AB	+	VIATRIS	EQ 20MG BASE	N021845	001	Jun 03, 2005	Feb	CAHN
----	---	---------	--------------	---------	-----	--------------	-----	------

VIAGRA

AB	+	VIATRIS	EQ 25MG BASE	N020895	001	Mar 27, 1998	Feb	CAHN
AB	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	Feb	CAHN
AB	+		EQ 100MG BASE	N020895	003	Mar 27, 1998	Feb	CAHN

SILODOSINCAPSULE;ORAL
SILODOSIN

@ UPSHER SMITH LABS	4MG	A213230	001	Jan 03, 2022	Feb DISC
@	8MG	A213230	002	Jan 03, 2022	Feb DISC

SIMVASTATINTABLET;ORAL
SIMVASTATIN

>A>	@ CHARTWELL RX	5MG	A077766	001	Dec 20, 2006	Mar CAHN
>A>	@	10MG	A077766	002	Dec 20, 2006	Mar CAHN
>A>	@	20MG	A077766	003	Dec 20, 2006	Mar CAHN
>A>	@	40MG	A077766	004	Dec 20, 2006	Mar CAHN
>A>	@	80MG	A077766	005	Dec 20, 2006	Mar CAHN
>D>	@ YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006	Mar CAHN
>D>	@	10MG	A077766	002	Dec 20, 2006	Mar CAHN
>D>	@	20MG	A077766	003	Dec 20, 2006	Mar CAHN
>D>	@	40MG	A077766	004	Dec 20, 2006	Mar CAHN
>D>	@	80MG	A077766	005	Dec 20, 2006	Mar CAHN

SIROLIMUS

>A>	GEL;TOPICAL					
>A>	HYFTOR					
>A>	+! NOBELPHARMA	0.2%	N213478	001	Mar 22, 2022	Mar NEWA

SODIUM CHLORIDESOLUTION;INTRAVENOUS
SODIUM CHLORIDE 23.4%

AP	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A212070	003	Feb 14, 2022	Feb NFTG
AP	+! HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Feb CFTG

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F 18

>D>	@ NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Mar CRLD
>A>	+ @	10-200mCi/ML	N022494	001	Jan 26, 2011	Mar CRLD

SODIUM NITROPRUSSIDEINJECTABLE;INJECTION
SODIUM NITROPRUSSIDE

>A>	AP	CAPLIN	25MG/ML	A211016	001	Nov 29, 2019	Mar CAHN
>D>	AP	HONG KONG	25MG/ML	A211016	001	Nov 29, 2019	Mar CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE;INJECTION
SODIUM PHOSPHATES

>A>	AP	FRESENIUS KABI USA	142MG/ML;276MG/ML	A209997	001	Mar 30, 2022	Mar NFTG
		SODIUM PHOSPHATES IN PLASTIC CONTAINER					
>D>	+!	HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Mar CFTG
>A>	AP	+!	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Mar CFTG

SODIUM POLYSTYRENE SULFONATESUSPENSION;ORAL, RECTAL
KIONEX

>D>	@ ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar CMFD	
>A>	AA	15GM/60ML	A040028	001	Sep 17, 2007	Mar CMFD	
		SPS					
>D>	+!	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Mar CTEC
>A>	AA	+!	15GM/60ML	A087859	001	Dec 08, 1982	Mar CTEC

SOFOBUVIRTABLET;ORAL
SOFOBUVIR

AB	TEVA PHARMS USA INC	400MG	A211353	001	Jan 27, 2022	Jan NFTG
	SOVALDI					
AB	+! GILEAD SCIENCES INC	400MG	N204671	001	Dec 06, 2013	Jan CFTG

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

@ AMNEAL PHARMS CO

5MG

A209719 001 May 20, 2019 Jan DISC

@

10MG

A209719 002 May 20, 2019 Jan DISC

SONIDEGIB PHOSPHATE

CAPSULE; ORAL

ODOMZO

+! SUN PHARM

EQ 200MG BASE

N205266 001 Jul 24, 2015 Feb CAHN

SOTALOL HYDROCHLORIDE

SOLUTION; ORAL

SOTYLIZE

>D> +! ARBOR PHARMS LLC

5MG/ML (5MG/ML)

N205108 001 Oct 22, 2014 Mar CAHN

>A> +! AZURITY

5MG/ML (5MG/ML)

N205108 001 Oct 22, 2014 Mar CAHN

STERILE WATER FOR INJECTION

LIQUID; N/A

STERILE WATER FOR INJECTION

AP ! MEDEFIL INC

100% (5ML)

A211188 004 Dec 02, 2019 Feb CTEC

AP NEPHRON

100% (5ML)

A211222 001 Feb 10, 2021 Feb CMFD

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

AP BE PHARMS

20MG/ML

A216003 001 Feb 07, 2022 Jan NEWA

>D> AP HONG KONG

20MG/ML

A214514 001 Oct 19, 2021 Mar CAHN

>A> AP MEITHEAL

20MG/ML

A214514 001 Oct 19, 2021 Mar CAHN

SUCRALFATE

SUSPENSION; ORAL

SUCRALFATE

>A> AB VISTAPHARM

1GM/10ML

A211884 001 Mar 15, 2022 Mar NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB NOVITIUM PHARMA

200MG/5ML; 40MG/5ML

A214330 001 Feb 08, 2022 Jan NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

@ STERISCIENCE

EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML)

A090314 001 Jun 10, 2010 Feb CAHN

@

EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML)

A090641 001 Jul 28, 2010 Feb CAHN

TADALAFIL

TABLET; ORAL

TADALAFIL

>A> AB1 AUSTARPHARMA

2.5MG

A208824 001 Oct 27, 2020 Mar CAHN

>A> AB1

5MG

A208824 002 Oct 27, 2020 Mar CAHN

>A> AB1

10MG

A208824 003 Oct 27, 2020 Mar CAHN

>A> AB1

20MG

A208824 004 Oct 27, 2020 Mar CAHN

>D> AB1 YANGLING BUCHANG

2.5MG

A208824 001 Oct 27, 2020 Mar CAHN

>D> AB1

5MG

A208824 002 Oct 27, 2020 Mar CAHN

>D> AB1

10MG

A208824 003 Oct 27, 2020 Mar CAHN

>D> AB1

20MG

A208824 004 Oct 27, 2020 Mar CAHN

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

TAFLUPROST

AT SANDOZ INC

0.0015%

A209040 001 Jan 28, 2022 Jan NEWA

TAVABOROLE

SOLUTION; TOPICAL

TAVABOROLE

>A> AB CHARTWELL RX

5%

A211963 001 Feb 03, 2021 Mar CAHN

>D> @ IDENTIRX

5%

A211963 001 Feb 03, 2021 Mar CAHN

>A>	<u>TECHNETIUM TC-99M SUCCIMER</u>								
>A>	POWDER; INTRAVENOUS								
>A>	NEPHROSCAN								
>A>	+	!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022	Mar	CAIN
>D>	<u>TECHNETIUM TC-99M SUCCIMER KIT</u>								
>D>	POWDER; INTRAVENOUS								
>D>	NEPHROSCAN								
>D>	+	!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022	Mar	CAIN
			+	!	N214993	001	Feb 18, 2022	Feb	NEWA
	<u>TECHNETIUM TC-99M TETROFOSMIN KIT</u>								
	INJECTABLE; INJECTION								
	MYOVUE								
	+	!	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996	Feb	CMFD
	<u>TEMOZOLOMIDE</u>								
	CAPSULE; ORAL								
	TEMOZOLOMIDE								
>D>	AB		ANI PHARMS	250MG	A203490	006	Jul 13, 2016	Mar	DISC
>A>			@	250MG	A203490	006	Jul 13, 2016	Mar	DISC
	AB		HERITAGE	5MG	A078879	001	Mar 01, 2010	Jan	CMFD
	AB			20MG	A078879	002	Mar 01, 2010	Jan	CMFD
	AB			100MG	A078879	003	Mar 01, 2010	Jan	CMFD
	AB			140MG	A078879	005	Mar 01, 2010	Jan	CMFD
	AB			180MG	A078879	006	Mar 01, 2010	Jan	CMFD
	AB			250MG	A078879	004	Mar 01, 2010	Jan	CMFD
	<u>TENAPANOR HYDROCHLORIDE</u>								
	TABLET; ORAL								
	IBSRELA								
	+	!	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Feb	CMFD
	<u>TERBINAFINE HYDROCHLORIDE</u>								
	TABLET; ORAL								
	TERBINAFINE HYDROCHLORIDE								
>D>			@ CHARTWELL	EQ 250MG BASE	A078199	001	Jul 02, 2007	Mar	CMFD
>A>	AB			EQ 250MG BASE	A078199	001	Jul 02, 2007	Mar	CMFD
	<u>TERBUTALINE SULFATE</u>								
	INJECTABLE; INJECTION								
	TERBUTALINE SULFATE								
>D>	AP	!	ATHENEX INC	1MG/ML	A076770	001	Apr 23, 2004	Mar	CAHN
>A>	AP	!	CHARTWELL INJECTABLE	1MG/ML	A076770	001	Apr 23, 2004	Mar	CAHN
	<u>TESTOSTERONE</u>								
	GEL; TRANSDERMAL								
	ANDROGEL								
	+	@	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jan	DISC
	+	@		1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jan	DISC
	+	@		25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	DISC
	+	@		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	DISC
	TESTOSTERONE								
AB1	!		ACTAVIS LABS UT INC	50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jan	CHRS
AB2	!		PADAGIS ISRAEL	1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jan	CHRS
	<u>TESTOSTERONE UNDECANOATE</u>								
	CAPSULE; ORAL								
	TLANDO								
>A>			ANTARES PHARMA INC	112.5MG	N208088	001	Mar 28, 2022	Mar	NEWA
	<u>TETRABENAZINE</u>								
	TABLET; ORAL								
	TETRABENAZINE								
			@ HIKMA	12.5MG	A209739	001	Apr 08, 2019	Feb	DISC
			@	25MG	A209739	002	Apr 08, 2019	Feb	DISC

THIOTHIXENE

	CAPSULE;ORAL						
	THIOTHIXENE						
AB	AMNEAL	1MG	A215456	001	Feb 28, 2022	Feb	NEWA
AB		2MG	A215456	002	Feb 28, 2022	Feb	NEWA
AB		5MG	A215456	003	Feb 28, 2022	Feb	NEWA
AB		10MG	A215456	004	Feb 28, 2022	Feb	NEWA

TICAGRELOR

	TABLET;ORAL						
	BRILINTA						
	+ ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Feb	CTEC
	TICAGRELOR						
	@ MYLAN	60MG	A208597	001	Jul 09, 2021	Feb	DISC
	@	90MG	A208597	002	Jul 09, 2021	Feb	DISC

TIMOLOL MALEATE

	SOLUTION/DROPS;OPHTHALMIC						
	TIMOPTIC IN OCUDOSE						
AT3	+! BAUSCH AND LOMB INC	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Feb	CAHN
AT3	+!	EQ 0.5% BASE	N019463	002	Nov 05, 1986	Feb	CAHN

TOFACITINIB CITRATE

	TABLET, EXTENDED RELEASE;ORAL						
	TOFACITINIB						
	@ ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Jan	DISC
	@	EQ 22MG BASE	A214264	002	Aug 19, 2021	Jan	DISC
	XELJANZ XR						
	+ PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jan	CTEC
	+!	EQ 22MG BASE	N208246	002	Dec 12, 2019	Jan	CTEC

TOLVAPTAN

	TABLET;ORAL						
	SAMSCA						
AB	+ OTSUKA	15MG	N022275	001	May 19, 2009	Feb	CFTG
	TOLVAPTAN						
AB	PAR PHARM INC	15MG	A206119	001	Feb 15, 2022	Feb	NFTG
AB		30MG	A206119	002	Feb 15, 2022	Feb	NEWA

TOPIRAMATE

	TABLET;ORAL						
	TOPIRAMATE						
>D>	AB UPSHER SMITH LABS	25MG	A078499	001	Jan 07, 2010	Mar	DISC
>A>	@	25MG	A078499	001	Jan 07, 2010	Mar	DISC
>D>	AB	50MG	A078499	002	Jan 07, 2010	Mar	DISC
>A>	@	50MG	A078499	002	Jan 07, 2010	Mar	DISC
>D>	AB	100MG	A078499	003	Jan 07, 2010	Mar	DISC
>A>	@	100MG	A078499	003	Jan 07, 2010	Mar	DISC
>D>	AB	200MG	A078499	004	Jan 07, 2010	Mar	DISC
>A>	@	200MG	A078499	004	Jan 07, 2010	Mar	DISC

TOPOTECAN HYDROCHLORIDE

	SOLUTION;INTRAVENOUS						
	TOPOTECAN HYDROCHLORIDE						
>D>	AP MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	DISC
>A>	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	DISC

TRIAMCINOLONE ACETONIDE

	AEROSOL, METERED;NASAL						
	NASACORT						
	@ CHATTEM SANOFI	0.055MG/INH	N019798	001	Jul 11, 1991	Jan	CAHN
	@	0.055MG/INH	N019798	001	Jul 11, 1991	Jan	CAHN
	FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR						
	ZILRETTA						
	+! PACIRA PHARMS INC	32MG/VIAL	N208845	001	Oct 06, 2017	Feb	CAHN
	INJECTABLE;INJECTION						
	TRIAMCINOLONE ACETONIDE						
AB	CUSTOPHARM INC	40MG/ML	A213543	001	Jan 19, 2022	Jan	NEWA
AB	LONG GROVE PHARMS	40MG/ML	A213543	001	Jan 19, 2022	Jan	CAHN

SPRAY, METERED;NASAL
 TRIAMCINOLONE ACETONIDE
 @ PERRIGO PHARMA INTL 0.055MG/SPRAY

A078104 001 Jul 30, 2009 Jan CAHN

TROSPIUM CHLORIDE

TABLET;ORAL
 TROSPIUM CHLORIDE

AB AMICI 20MG

A215781 001 Feb 16, 2022 Feb NEWA

UPADACITINIB

TABLET, EXTENDED RELEASE;ORAL
 RINVOQ

+ ABBVIE INC 15MG

N211675 001 Aug 16, 2019 Jan CHRS

+! 30MG

N211675 002 Jan 14, 2022 Jan NEWA

>A> +! 45MG

N211675 003 Mar 16, 2022 Mar NEWA

URSODIOL

CAPSULE;ORAL
 URSODIOL

@ VGYAAN 300MG

A214329 001 Jul 28, 2021 Feb DISC

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL
 VALGANCICLOVIR HYDROCHLORIDE

AB AIRIS PHARMA PVT LTD 50MG/ML

A210169 001 Feb 17, 2022 Feb NEWA

TABLET;ORAL

>D> VALGANCICLOVIR HYDROCHLORIDE

>D> AB MYLAN EQ 450MG BASE

A205151 001 Mar 03, 2021 Mar DISC

>A> @ EQ 450MG BASE

A205151 001 Mar 03, 2021 Mar DISC

VALPROIC ACID

SYRUP;ORAL
 VALPROIC ACID

>D> AA WOCKHARDT BIO AG 250MG/5ML

A070868 001 Jul 01, 1986 Mar DISC

>A> @ 250MG/5ML

A070868 001 Jul 01, 1986 Mar DISC

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION
 VANCOCIN HYDROCHLORIDE

@ STERISCIENCE EQ 500MG BASE/VIAL

A060180 001 Jan CAHN

@ EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984 Jan CAHN

@ EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987 Jan CAHN

@ EQ 500MG BASE/VIAL

A062812 001 Nov 17, 1987 Jan CAHN

@ EQ 1GM BASE/VIAL

A060180 002 Mar 21, 1986 Jan CAHN

@ EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986 Jan CAHN

@ EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987 Jan CAHN

@ EQ 1GM BASE/VIAL

A062812 002 Nov 17, 1987 Jan CAHN

@ EQ 10GM BASE/VIAL

A062812 003 Nov 17, 1987 Jan CAHN

VANCOMYCIN HYDROCHLORIDE

AP KNACK EQ 500MG BASE/VIAL

A213059 001 Feb 15, 2022 Feb NEWA

AP EQ 750MG BASE/VIAL

A213059 002 Feb 15, 2022 Feb NEWA

AP EQ 1GM BASE/VIAL

A213059 003 Feb 15, 2022 Feb NEWA

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+ @ MYLAN LABS LTD EQ 250MG BASE/VIAL

N209481 001 Jul 10, 2018 Feb DISC

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL
 LEVITRA

+ @ BAYER HLTHCARE EQ 20MG BASE

N021400 004 Aug 19, 2003 Feb DISC

VARDENAFIL HYDROCHLORIDE

AB ! ZYDUS PHARMS EQ 20MG BASE

A208960 004 Oct 31, 2018 Feb CHRS

VARENICLINE TARTRATE

TABLET;ORAL
 CHANTIX

AB + PF PRISM CV EQ 1MG BASE

N021928 002 May 10, 2006 Feb CHRS

VARENICLINE TARTRATE

AB ! PAR PHARM INC EQ 1MG BASE

A201785 002 Aug 11, 2021 Feb CHRS

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

@	YICHANG HUMANWELL	EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Jan	DISC
@		EQ 75MG BASE	A214654	002	Aug 06, 2021	Jan	DISC
@		EQ 150MG BASE	A214654	003	Aug 06, 2021	Jan	DISC

VERAPAMIL HYDROCHLORIDEINJECTABLE;INJECTION
VERAPAMIL HYDROCHLORIDE

>A>	AP	ACIC PHARMS	2.5MG/ML	A215829	001	Mar 17, 2022	Mar	NEWA
TABLET;ORAL								
VERAPAMIL HYDROCHLORIDE								
>A>		@ CHARTWELL RX	40MG	A073168	001	Jul 31, 1992	Mar	CAHN
>A>		@	80MG	A071423	001	May 24, 1988	Mar	CAHN
>A>		@	120MG	A071424	001	May 25, 1988	Mar	CAHN
>D>		@ YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992	Mar	CAHN
>D>		@	80MG	A071423	001	May 24, 1988	Mar	CAHN
>D>		@	120MG	A071424	001	May 25, 1988	Mar	CAHN

VIGABATRINFOR SOLUTION;ORAL
VIGABATRIN

>A>	AA	LUPIN LTD	500MG/PACKET	A211790	001	Mar 10, 2022	Mar	NEWA
TABLET;ORAL								
VIGABATRIN								
	AB	ZYDUS	500MG	A215707	001	Jan 19, 2022	Jan	NEWA

VORTIOXETINE HYDROBROMIDETABLET;ORAL
TRINTELLIX

>D>	AB	+ TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Mar	CTEC
>A>		+	EQ 5MG BASE	N204447	001	Sep 30, 2013	Mar	CTEC
>D>	AB	+	EQ 10MG BASE	N204447	002	Sep 30, 2013	Mar	CTEC
>A>		+	EQ 10MG BASE	N204447	002	Sep 30, 2013	Mar	CTEC
>D>	AB	+!	EQ 20MG BASE	N204447	004	Sep 30, 2013	Mar	CTEC
>A>		+!	EQ 20MG BASE	N204447	004	Sep 30, 2013	Mar	CTEC
>D> VORTIOXETINE HYDROBROMIDE								
>D>	AB	ZYDUS PHARMS	EQ 5MG BASE	A211146	001	Sep 17, 2021	Mar	DISC
>A>		@	EQ 5MG BASE	A211146	001	Sep 17, 2021	Mar	DISC
>D>	AB		EQ 10MG BASE	A211146	002	Sep 17, 2021	Mar	DISC
>A>		@	EQ 10MG BASE	A211146	002	Sep 17, 2021	Mar	DISC
>D>	AB		EQ 20MG BASE	A211146	003	Sep 17, 2021	Mar	DISC
>A>		@	EQ 20MG BASE	A211146	003	Sep 17, 2021	Mar	DISC

ZALEPLONCAPSULE;ORAL
ZALEPLON

>A>	AB	CHARTWELL MOLECULAR	5MG	A077505	001	Jun 20, 2008	Mar	CAHN
>A>	AB		10MG	A077505	002	Jun 20, 2008	Mar	CAHN
>D>	AB	CIPLA LTD	5MG	A077505	001	Jun 20, 2008	Mar	CAHN
>D>	AB		10MG	A077505	002	Jun 20, 2008	Mar	CAHN

ZINC CHLORIDEINJECTABLE;INJECTION
ZINC CHLORIDE

@	EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Feb	DISC
ZINC CHLORIDE IN PLASTIC CONTAINER							
+!	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Feb	CTEC

ZIPRASIDONE HYDROCHLORIDECAPSULE;ORAL
GEODON

AB	+!	VIATRIS	EQ 20MG BASE	N020825	001	Feb 05, 2001	Jan	CAHN
AB	+		EQ 40MG BASE	N020825	002	Feb 05, 2001	Jan	CAHN
AB	+		EQ 60MG BASE	N020825	003	Feb 05, 2001	Jan	CAHN
AB	+		EQ 80MG BASE	N020825	004	Feb 05, 2001	Jan	CAHN

ZIPRASIDONE MESYLATEINJECTABLE; INTRAMUSCULAR
GEODON

AP	+	VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CPOT
AP	+		EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Jan CAHN
ZIPRASIDONE MESYLATE							
AP		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CPOT
POWDER; INTRAMUSCULAR GEODON							
AP	+	VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CDFR
ZIPRASIDONE MESYLATE							
AP		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CDFR

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

>A>	AB	CHARTWELL MOLECULAR	5MG	A077388	001	Jul 30, 2012	Mar CAHN
>A>	AB		10MG	A077388	002	Jul 30, 2012	Mar CAHN
>D>	AB	CIPLA LTD	5MG	A077388	001	Jul 30, 2012	Mar CAHN
>D>	AB		10MG	A077388	002	Jul 30, 2012	Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

AUROBINDO PHARMA LTD 250MG;250MG;65MG

A 211695 001 Feb 02, 2022 Jan NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

TARO PHARMS 0.1%

A 215940 001 Jan 14, 2022 Jan NEWA

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D> @ ACTAVIS MID ATLANTIC 5MG/5ML A 090378 002 May 09, 2008 Mar CAHN

>A> @ CHARTWELL RX 5MG/5ML A 090378 002 May 09, 2008 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D> @ ACTAVIS MID ATLANTIC 5MG/5ML A 090378 001 May 09, 2008 Mar CAHN

>A> @ CHARTWELL RX 5MG/5ML A 090378 001 May 09, 2008 Mar CAHN

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

>A> AKORN 1% A 209484 001 Nov 21, 2018 Mar CMKT

ESOMEPRAZOLE MAGNESIUM

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

+ @ DEXCEL PHARMA EQ 20MG BASE

N 214278 001 Oct 20, 2020 Jan DISC

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

VKT PHARMA 10MG
20MG

A 215822 001 Jan 28, 2022 Jan NEWA

A 215822 002 Jan 28, 2022 Jan NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+! CHATTEM SANOFI 60MG;120MG N 020786 002 Jan 24, 2011 Jan CAHN

+! 60MG;120MG N 020786 002 Jan 24, 2011 Jan CAHN

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+! CHATTEM SANOFI 180MG;240MG N 021704 002 Jan 24, 2011 Jan CAHN

+! 180MG;240MG N 021704 002 Jan 24, 2011 Jan CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

>A> DR REDDYS LABS LTD 600MG A 215932 001 Mar 15, 2022 Mar NEWA

>A> 1.2GM A 215932 002 Mar 15, 2022 Mar NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

L PERRIGO CO 600MG;60MG

A 214407 001 Feb 01, 2022 Jan NEWA

1.2GM;120MG

A 214407 002 Feb 01, 2022 Jan NEWA

IVERMECTIN

LOTION;TOPICAL

IVERMECTIN

>A> TEVA PHARMS USA 0.5% A 212485 001 Mar 21, 2022 Mar NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALWAY

>D> BAUSCH EQ 0.035% BASE A 208158 001 Sep 24, 2020 Mar CAHN

>D> + BAUSCH AND LOMB EQ 0.035% BASE N 021996 002 Feb 11, 2015 Mar CPOT

>A> BAUSCH AND LOMB INC EQ 0.025% BASE A 208158 001 Sep 24, 2020 Mar CAHN

CHILDREN'S ALWAY

>A> + BAUSCH AND LOMB EQ 0.025% BASE N 021996 002 Feb 11, 2015 Mar CPOT

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI 2.5MG/5ML N209090 001 Jan 31, 2017 Jan CAHN

TABLET;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI 5MG N209089 001 Jan 31, 2017 Jan CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

PERRIGO PHARMA INTL 5%

A091344 001 Apr 28, 2011 Jan CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL

NASONEX 24HR ALLERGY

>A> +! PERRIGO PHARMA INTL 0.05MG/SPRAY N215712 001 Mar 17, 2022 Mar NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+ @ BAYER 220MG;120MG N021076 001 Nov 29, 1999 Jan DISC

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

! PERRIGO 220MG;120MG A076518 001 Mar 17, 2004 Jan CHRS

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+! DEXCEL PHARMA 20MG N209400 001 Jul 05, 2017 Feb CHRS

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

>D> +! BAYER HEALTHCARE LLC 20MG;1.1GM N022281 001 Dec 01, 2009 Mar CAHN

>A> +! RILEY CONSUMER 20MG;1.1GM N022281 001 Dec 01, 2009 Mar CAHN

FOR SUSPENSION;ORAL

ZEGERID OTC

>D> +! BAYER HEALTHCARE LLC 20MG/PACKET;1.68GM/PACKET N022283 001 Jun 17, 2013 Mar CAHN

>A> +! RILEY CONSUMER 20MG/PACKET;1.68GM/PACKET N022283 001 Jun 17, 2013 Mar CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

+ @ ROXANE 1GM/ML N018551 001 Feb 19, 1982 Jan CRLD

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

ZANTAC 150

+ @ CHATTEM SANOFI EQ 150MG BASE N021698 001 Aug 31, 2004 Jan CAHN

+ @ ZANTAC 150 N021698 002 Mar 13, 2007 Jan CAHN

ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE N020520 001 Dec 19, 1995 Jan CAHN

TABLET, EFFERVESCENT;ORAL

ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE N020745 001 Feb 26, 1998 Jan CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+! CHATTEM SANOFI 0.055MG/SPRAY N020468 002 Oct 11, 2013 Jan CAHN

+! 0.055MG/SPRAY N020468 002 Oct 11, 2013 Jan CAHN

TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2022

NO MARCH 2022 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2022 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	>A> 11255842	Jan 10, 2040	U-3322			
<u>ABROCITINIB - CIBINOO</u>						
N 213871 001	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINOO</u>						
N 213871 002	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINOO</u>						
N 213871 003	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	10004743	Jul 05, 2030	DP		ODE-115	Apr 15, 2023
	10004743*PED	Jan 05, 2031			ODE-230	Jan 12, 2025
	8426586	Oct 10, 2029	DS		PED	Oct 15, 2023
	8426586*PED	Apr 10, 2030			PED	Jul 12, 2025
	8545884	Dec 19, 2029	DP			
	8545884*PED	Jun 19, 2030				
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	10004743	Jul 05, 2030	DP		ODE-115	Apr 15, 2023
	10004743*PED	Jan 05, 2031			ODE-230	Jan 12, 2025
	8426586	Oct 10, 2029	DS		PED	Oct 15, 2023
	8426586*PED	Apr 10, 2030			PED	Jul 12, 2025
	8545884	Dec 19, 2029	DP			
	8545884*PED	Jun 19, 2030				
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	10004743	Jul 05, 2030	DP		ODE-115	Apr 15, 2023
	10004743*PED	Jan 05, 2031			ODE-230	Jan 12, 2025
	8426586	Oct 10, 2029	DS		PED	Oct 15, 2023
	8426586*PED	Apr 10, 2030			PED	Jul 12, 2025
	8545884	Dec 19, 2029	DP			
	8545884*PED	Jun 19, 2030				
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11197835	Dec 02, 2030	U-2106			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11197835	Dec 02, 2030	U-2106			
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001	>A> 11268128	Jun 29, 2032	U-2956			
	>A> 11274331	Jun 29, 2032	U-2956			
	>A> 11274332	Jun 29, 2032	U-2956			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001	>A> 11268128	Jun 29, 2032	U-2956			
	>A> 11274331	Jun 29, 2032	U-2956			
	>A> 11274332	Jun 29, 2032	U-2956			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	11235169	Oct 15, 2040	U-3303			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	9084765	Mar 10, 2031	U-1744			
	9084765	Mar 10, 2031	U-2754			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	11253474	Feb 24, 2041	DP U-3309			
	11253474	Feb 24, 2041	DP U-3310			
	11253474	Feb 24, 2041	DP U-3311			
<u>AMPHOTERICIN B - AMPHOTERICIN B</u>						
A 212514 001					CGT	Aug 14, 2022
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>APOMORPHINE HYDROCHLORIDE - APOMORPHINE HYDROCHLORIDE</u>						
A 212025 001					CGT	Aug 24, 2022
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	11229378	Jul 11, 2031	DP			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	8829195	May 13, 2033	DS U-1374		ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	8829195	May 13, 2033	DS U-1374		ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001					ODE-377	Oct 07, 2028
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	>A> 11261198	Sep 25, 2038	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	>A> 11261198	Sep 25, 2038	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	>A> 11261198	Sep 25, 2038	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	>A> 11261198	Sep 25, 2038	DP			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	11230530	Mar 09, 2035	U-3300			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	11230530	Mar 09, 2035	U-3300			
<u>BETAINE - BETAINE</u>						
A 214864 001					CGT	Aug 02, 2022
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002					NCE ODE-378	Feb 07, 2023 Oct 07, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	7323463	Jan 19, 2023	DP	Y		
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					NP	Dec 15, 2024
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	>A> 11278494	Jan 22, 2041	DP U-3250			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	>A> 11278494	Jan 22, 2041	DP U-3250			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	11253504	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	11253504	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	11253504	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	11253504	Mar 13, 2034	U-3118			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	>A> 11278544	Apr 21, 2024	U-1583			
<u>CABOTEGRAVIR - APRETUDE</u>						
N 215499 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	8410103	Apr 28, 2026	DS DP			
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001					>A> M-273	Jan 31, 2025
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	11224597	Sep 15, 2031	DP U-3060		>A> D-184	Jan 31, 2025
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11224597	Sep 15, 2031	DP U-3060		>A> D-184	Jan 31, 2025
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11253528	Mar 14, 2034	DP			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	>A> 11253494	Mar 15, 2033	U-3323			
	>A> 11253494	Mar 15, 2033	U-3324			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11033521	Mar 28, 2039	DP U-219			
	11033521	Mar 28, 2039	DP U-3304			
	11033521	Mar 28, 2039	DP U-3305			
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	>A> RE48960	Jun 28, 2025	DS DP U-3087			
	>A> RE48960	Jun 28, 2025	DS DP U-3088			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	>A> 11246863	Nov 27, 2038	DP			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2023	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11207332	Nov 20, 2028	DP U-3280			
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650 001	11129896	Sep 22, 2036	U-3293		NP GAIN	Dec 07, 2024 Dec 07, 2029
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	>A> 11254649	Jun 30, 2036	DS DP U-1776			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 003	>A> 10993952	Feb 15, 2036	DP			
<u>DAPSONE - ACZONE</u>						
N 207154 001	>A> 11273132	Nov 18, 2033	DP			
<u>DAPTOMYCIN - DAPZURA RT</u>						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	11168058	Feb 27, 2038	DS DP			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11236328	Jun 22, 2032	U-3301			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	>A> 7728143	Jun 19, 2031	DS			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	>A> 7728143	Jun 19, 2031	DS			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	11241414	Mar 27, 2029	DP			
<u>DIGOXIN - DIGOXIN</u>						
A 214982 001					CGT	Aug 16, 2022
<u>DIHYDROERGOTAMINE MESYLATE - TRUDHESA</u>						
N 213436 001	>A> 11266799	Nov 05, 2036	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	>A> 11246850	Nov 16, 2035	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	>A> 11246850	Nov 16, 2035	U-1384			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	11234985	Jan 24, 2031	DP U-257			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	>A> 10016372	Jul 26, 2037	U-3334			
	>A> 10300025	Jul 26, 2037	DP			
	>A> 10307379	Jul 26, 2037	DP			
	>A> 10835499	May 20, 2038	DP U-3334			
	>A> 10966936	Aug 11, 2038	DP U-3334			
	>A> 11103463	Jul 26, 2037	U-3334			
	>A> 9993466	Jul 26, 2037	DP			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 002	>A> 10016372	Jul 26, 2037	U-3334			
	>A> 10300025	Jul 26, 2037	DP			
	>A> 10307379	Jul 26, 2037	DP			
	>A> 10835499	May 20, 2038	DP U-3334			
	>A> 10966936	Aug 11, 2038	DP U-3334			
	>A> 11103463	Jul 26, 2037	U-3334			
	>A> 9993466	Jul 26, 2037	DP			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394			
	8486975	Oct 07, 2031	DS DP U-2630			
	8486975	Oct 07, 2031	DS DP U-3308			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395			
	8486975	Oct 07, 2031	DS DP U-2629			
	8486975	Oct 07, 2031	DS DP U-3307			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	11234954	Jan 18, 2028	U-620			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	11234954	Jan 18, 2028	U-620			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	11253472	Aug 06, 2028	DS DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	11202772	Apr 13, 2037	DP			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11213519	Jan 03, 2028	U-2720			
<u>ELBASVIR; GRAZOPREXIVIR - ZEPATIER</u>						
N 208261 001				NPP		Dec 09, 2024
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	11229627	Mar 14, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	11229627	Mar 14, 2033	DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	>A> 9949997	May 17, 2034	U-2292		>A> M-82	Feb 24, 2025
	>A> 9949997	May 17, 2034	U-3199			
	>A> 9949997	May 17, 2034	U-3325			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Apr 17, 2025	DS DP			
	8754065	Aug 15, 2032	DS DP U-1663			
	9296769	Aug 15, 2032	DS DP U-1663			
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	11173141	Mar 25, 2036	DP			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	9474754	Aug 05, 2033	U-2802			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	>A> 11253515	Jul 18, 2038	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	>A> 11253515	Jul 18, 2038	DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11241400	May 16, 2040	U-3183			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAIVA</u>						
N 211109 001	10961190	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAIVA</u>						
N 211109 002	10961190	Oct 19, 2037	DS			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	>A> 11266661	Feb 02, 2034	U-2316			
	>A> 11266661	Feb 02, 2034	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	>A> 11266661	Feb 02, 2034	U-2316			
	>A> 11266661	Feb 02, 2034	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	9301920	Nov 21, 2032	DP U-2439			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	>A> 10452815	Jun 29, 2038	U-2859		>A> NP	Jun 25, 2023
	>A> 10452815*PED	Dec 29, 2038			>A> ODE-312	Jun 25, 2027
	>A> 10478441	May 03, 2033	U-2860		>A> PED	Dec 25, 2023
	>A> 10478441*PED	Nov 03, 2033			>A> PED	Dec 25, 2027
	>A> 10478442	May 03, 2033	U-2860			
	>A> 10478442*PED	Nov 03, 2033				
	>A> 10603290	Aug 02, 2037	U-2861			
	>A> 10603290*PED	Feb 02, 2038				
	>A> 10947183	Dec 20, 2036	DS DP			
	>A> 10947183*PED	Jun 20, 2037				
	>A> 10950331	Sep 28, 2035	U-3098			
	>A> 10950331*PED	Mar 28, 2036				
	>A> 11040018	Aug 02, 2037	U-2861			
	>A> 11040018*PED	Feb 02, 2038				
	>A> 9549909	May 03, 2033	U-2858			
	>A> 9549909*PED	Nov 03, 2033				
	>A> 9603814	May 03, 2033	U-2858			
	>A> 9603814*PED	Nov 03, 2033				
	>A> 9603815	May 03, 2033	U-2858			
	>A> 9603815*PED	Nov 03, 2033				
	>A> 9610260	May 03, 2033	U-2858			
	>A> 9610260*PED	Nov 03, 2033				
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028			U-2555	
	7754702	Feb 15, 2028			U-2556	
	7754702	Feb 15, 2028			U-2557	
	7754702	Feb 15, 2028			U-3312	
	7754702	Feb 15, 2028			U-3313	
	7754702	Feb 15, 2028			U-3314	
	8895612	Jan 08, 2027			U-1620	
	8895612	Jan 08, 2027			U-3050	
	8895612	Jan 08, 2027			U-3051	
	8895612	Jan 08, 2027			U-3115	
	8895612	Jan 08, 2027			U-3116	
	8895612	Jan 08, 2027			U-3315	
	8895612	Jan 08, 2027			U-3316	
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028			U-3312	
	7754702	Feb 15, 2028			U-3313	
	7754702	Feb 15, 2028			U-3314	
	8895612	Jan 08, 2027			U-3115	
	8895612	Jan 08, 2027			U-3116	
	8895612	Jan 08, 2027			U-3315	
	8895612	Jan 08, 2027			U-3316	
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	11234938	Nov 26, 2034				
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	>A> 9993483	Jul 02, 2030				
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	RE48898	Jan 19, 2026				
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	RE48898	Jan 19, 2026				
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828 001					>A> ODE-383	Aug 21, 2026
					>A> W	Aug 21, 2026
<u>GALLIUM GA-68 GOZETOTIDE - ILLUCCIX</u>						
N 214032 001	11027031	Jul 28, 2035			U-3317	
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	11028392	Oct 03, 2034	DS DP U-2672			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	11246866	Jun 24, 2036			DP	
	11246866*PED	Dec 24, 2036				
	RE48923	May 08, 2035			DS	
	RE48923*PED	Nov 08, 2035				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	RE48923	May 08, 2035			DS	
	RE48923*PED	Nov 08, 2035				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	>A> 11278683	Aug 16, 2026	DP			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001					NPP	Aug 18, 2024
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	11235168	Jan 04, 2038	U-2250			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	11213504	Apr 29, 2030	U-3292			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	11213504	Apr 29, 2030	U-3292			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11202752	Apr 30, 2030	U-1455			
	11202752	Apr 30, 2030	U-172			
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3272		NCE	Dec 22, 2026
	10131907	Aug 24, 2028	DS DP U-3272			
	10266825	Nov 04, 2023	U-3272			
	10273477	Mar 08, 2024	DS			
	10590418	Jul 19, 2022	U-3272			
	10669544	Mar 08, 2024	DS			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036	U-3272			
	11078485	Nov 04, 2023	DS U-3272			
	8106022	Dec 12, 2029	DS DP U-3272			
	8222222	Dec 29, 2027	U-3272			
	8232383	Feb 20, 2023	DS DP			
	8546143	Apr 23, 2022	DS U-3272			
	8809292	May 10, 2027	DS DP U-3272			
	8828956	Dec 04, 2028	DS DP U-3272			
	9074213	Mar 09, 2022	DS U-3272			
	9370582	Dec 04, 2028	DS DP U-3272			
	9708610	Jan 01, 2024	DS DP U-3272			
	9708615	Mar 08, 2024	DS			
<u>ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE</u>						
A 211290 001					CGT	Jun 20, 2022
<u>KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN</u>						
N 022388 001	>A> 9474746	Mar 27, 2028	DP	>A>	NP	Feb 25, 2025
	>A> 9962376	Jun 27, 2030	DP			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001					NPP	Oct 14, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001					NPP	Oct 14, 2024
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 001					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 002					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 003					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 004					PC	Aug 30, 2022
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					>A> M-272	Dec 19, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					>A> M-272	Dec 19, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001					NPP	Dec 10, 2024
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	10098877	Jan 10, 2026	U-3283			
	10517868	Jan 10, 2026	U-3283			
	10835530	Jan 10, 2026	U-3283			
	11020393	Mar 02, 2040	U-3282			
	>A> 11278547	Mar 02, 2040	U-3282			
	9918984	Jan 10, 2026	U-3283			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	>A> 11278623	May 10, 2031	DP			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11219597	May 03, 2033	U-3278			
	11219597	May 03, 2033	U-3279			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11219596	May 03, 2033	U-2985			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001	>A> 11261447	Nov 20, 2038	DS DP U-2995			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	11026951	Dec 03, 2034	U-3274			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	11229647	Feb 12, 2040	U-3290		ODE-379	Sep 29, 2028
	11260053	May 26, 2031	U-3290			
<u>MARAVIROC - MARAVIROC</u>						
A 203347 001					PC	Aug 06, 2022
<u>MARAVIROC - MARAVIROC</u>						
A 203347 002					PC	Aug 06, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001					NCE	Nov 23, 2026
<u>MELOXICAM - ANJESO</u>						
N 210583 001	11253478	May 26, 2030	DP U-3318			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	10632114	May 03, 2032	U-3320		>A> NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	10632114	May 03, 2032	U-3320		>A> NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	10632114	May 03, 2032	U-3320		>A> NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	9980961	May 03, 2032	U-3319			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	10016443	Sep 04, 2034	U-3297			
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP	U-3297		
	10548907	Sep 04, 2034	U-3297			
	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			
	9078923	Sep 04, 2034	DP	U-3297		
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP	U-3297		
	9937189	Sep 04, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	>A> 11135155	Aug 26, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457 001	>A> 10143792	May 24, 2031	U-2476			
	>A> 10314977	Nov 23, 2024	DP			
	>A> 10322239	Feb 28, 2031	U-1907			
	>A> 10335549	Apr 30, 2025	DP			
	>A> 10737028	Nov 23, 2024	DP			
	>A> 7731690	Jan 15, 2025	DP			
	>A> 7918823	Nov 23, 2024	DP			
	>A> 7947017	Mar 12, 2028	DP			
	>A> 8016788	Mar 21, 2025	DP			
	>A> 8313466	Nov 23, 2024	DP			
	>A> 8361029	Nov 23, 2024	DP			
	>A> 8425462	Nov 23, 2024	DP			
	>A> 8608698	Nov 23, 2024	DP			
	>A> 8939943	Feb 28, 2031	DP			
	>A> 9022022	Feb 28, 2031	DP			
	>A> 9056170	Nov 23, 2024	DP			
	>A> 9474869	Feb 28, 2031	DP	U-1907		
	>A> 9737669	Nov 23, 2024	DP			
	>A> 9814838	Feb 28, 2031	DP			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	11090280	Mar 03, 2026	DP	U-1731		
	11090280	Mar 03, 2026	DP	U-1732		
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	11207306	Apr 16, 2038	U-2804			
<u>OBETICHOIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Feb 21, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Feb 21, 2027	DS DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11241425	Aug 23, 2031			U-3137	
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11241425	Aug 23, 2031			U-3137	
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11241425	Aug 23, 2031			U-3137	
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11241425	Aug 23, 2031			U-3137	
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 8071579	Aug 12, 2027	U-2101		>A> I-885	Mar 11, 2025
	>A> 8071579	Aug 12, 2027	U-2103			
	>A> 8071579	Aug 12, 2027	U-2480			
	>A> 8071579	Aug 12, 2027	U-2481			
	>A> 8071579	Aug 12, 2027	U-2482			
	>A> 8071579	Aug 12, 2027	U-2483			
	>A> 8071579	Aug 12, 2027	U-2716			
	>A> 8071579	Aug 12, 2027	U-2819			
	>A> 8071579	Aug 12, 2027	U-2820			
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2822			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
	>A> 8071579	Aug 12, 2027	U-3333			
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2103			
	>A> 8143241	Aug 12, 2027	U-2480			
	>A> 8143241	Aug 12, 2027	U-2481			
	>A> 8143241	Aug 12, 2027	U-2482			
	>A> 8143241	Aug 12, 2027	U-2483			
	>A> 8143241	Aug 12, 2027	U-2716			
	>A> 8143241	Aug 12, 2027	U-2819			
	>A> 8143241	Aug 12, 2027	U-2820			
	>A> 8143241	Aug 12, 2027	U-2821			
	>A> 8143241	Aug 12, 2027	U-2822			
	>A> 8143241	Aug 12, 2027	U-2823			
	>A> 8143241	Aug 12, 2027	U-2824			
	>A> 8143241	Aug 12, 2027	U-2832			
	>A> 8143241	Aug 12, 2027	U-2833			
	>A> 8143241	Aug 12, 2027	U-3333			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2103			
	>A> 8859562	Aug 04, 2031	U-2480			
	>A> 8859562	Aug 04, 2031	U-2481			
	>A> 8859562	Aug 04, 2031	U-2482			
	>A> 8859562	Aug 04, 2031	U-2483			
	>A> 8859562	Aug 04, 2031	U-2716			
	>A> 8859562	Aug 04, 2031	U-2819			
	>A> 8859562	Aug 04, 2031	U-2820			
	>A> 8859562	Aug 04, 2031	U-2821			
	>A> 8859562	Aug 04, 2031	U-2822			
	>A> 8859562	Aug 04, 2031	U-2823			
	>A> 8859562	Aug 04, 2031	U-2824			
	>A> 8859562	Aug 04, 2031	U-2832			
	>A> 8859562	Aug 04, 2031	U-2833			
	>A> 8859562	Aug 04, 2031	U-3333			
	>A> 8912187	Mar 12, 2024	U-2101			
	>A> 8912187	Mar 12, 2024	U-2480			
	>A> 8912187	Mar 12, 2024	U-2481			
	>A> 8912187	Mar 12, 2024	U-2482			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 8912187	Mar 12, 2024	U-2483			
	>A> 8912187	Mar 12, 2024	U-2819			
	>A> 8912187	Mar 12, 2024	U-2820			
	>A> 8912187	Mar 12, 2024	U-2821			
	>A> 8912187	Mar 12, 2024	U-2822			
	>A> 8912187	Mar 12, 2024	U-2823			
	>A> 8912187	Mar 12, 2024	U-2824			
	>A> 8912187	Mar 12, 2024	U-3333			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 8071579	Aug 12, 2027	U-2101		>A> I-885	Mar 11, 2025
	>A> 8071579	Aug 12, 2027	U-2103			
	>A> 8071579	Aug 12, 2027	U-2480			
	>A> 8071579	Aug 12, 2027	U-2481			
	>A> 8071579	Aug 12, 2027	U-2482			
	>A> 8071579	Aug 12, 2027	U-2483			
	>A> 8071579	Aug 12, 2027	U-2716			
	>A> 8071579	Aug 12, 2027	U-2819			
	>A> 8071579	Aug 12, 2027	U-2820			
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2822			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
	>A> 8071579	Aug 12, 2027	U-3333			
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2103			
	>A> 8143241	Aug 12, 2027	U-2480			
	>A> 8143241	Aug 12, 2027	U-2481			
	>A> 8143241	Aug 12, 2027	U-2482			
	>A> 8143241	Aug 12, 2027	U-2483			
	>A> 8143241	Aug 12, 2027	U-2716			
	>A> 8143241	Aug 12, 2027	U-2819			
	>A> 8143241	Aug 12, 2027	U-2820			
	>A> 8143241	Aug 12, 2027	U-2821			
	>A> 8143241	Aug 12, 2027	U-2822			
	>A> 8143241	Aug 12, 2027	U-2823			
	>A> 8143241	Aug 12, 2027	U-2824			
	>A> 8143241	Aug 12, 2027	U-2832			
	>A> 8143241	Aug 12, 2027	U-2833			
	>A> 8143241	Aug 12, 2027	U-3333			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2103			
	>A> 8859562	Aug 04, 2031	U-2480			
	>A> 8859562	Aug 04, 2031	U-2481			
	>A> 8859562	Aug 04, 2031	U-2482			
	>A> 8859562	Aug 04, 2031	U-2483			
	>A> 8859562	Aug 04, 2031	U-2716			
	>A> 8859562	Aug 04, 2031	U-2819			
	>A> 8859562	Aug 04, 2031	U-2820			
	>A> 8859562	Aug 04, 2031	U-2821			
	>A> 8859562	Aug 04, 2031	U-2822			
	>A> 8859562	Aug 04, 2031	U-2823			
	>A> 8859562	Aug 04, 2031	U-2824			
	>A> 8859562	Aug 04, 2031	U-2832			
	>A> 8859562	Aug 04, 2031	U-2833			
	>A> 8859562	Aug 04, 2031	U-3333			
	>A> 8912187	Mar 12, 2024	U-2101			
	>A> 8912187	Mar 12, 2024	U-2480			
	>A> 8912187	Mar 12, 2024	U-2481			
	>A> 8912187	Mar 12, 2024	U-2482			
	>A> 8912187	Mar 12, 2024	U-2483			
	>A> 8912187	Mar 12, 2024	U-2819			
	>A> 8912187	Mar 12, 2024	U-2820			
	>A> 8912187	Mar 12, 2024	U-2821			
	>A> 8912187	Mar 12, 2024	U-2822			
	>A> 8912187	Mar 12, 2024	U-2823			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 8912187	Mar 12, 2024	U-2824			
	>A> 8912187	Mar 12, 2024	U-3333			
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001	>A> 8153632	Jan 17, 2029	DS DP U-3331		>A> NCE	Feb 28, 2027
	>A> 8153632	Jan 17, 2029	DS DP U-3332			
	>A> 8980873	Mar 25, 2030	DS DP U-3331			
	>A> 8980873	Mar 25, 2030	DS DP U-3332			
	>A> 9573964	May 05, 2028	U-3331			
	>A> 9573964	May 05, 2028	U-3332			
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001	10881747	Aug 26, 2033	DS DP U-3291			
	9061057	Aug 26, 2033	DS DP U-3291			
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP U-3291			
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP U-3291			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	>A> 11266750	Mar 16, 2037	U-665			
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	>A> 11266750	Mar 16, 2037	U-665			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	>A> 11192897	Dec 12, 2033	DS U-1700			
	>A> 11192897	Dec 12, 2033	DS U-1701			
	>A> 11192897	Dec 12, 2033	DS U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	>A> 11192897	Dec 12, 2033	DS U-1700			
	>A> 11192897	Dec 12, 2033	DS U-1701			
	>A> 11192897	Dec 12, 2033	DS U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	>A> 11192897	Dec 12, 2033	DS U-1700			
	>A> 11192897	Dec 12, 2033	DS U-1701			
	>A> 11192897	Dec 12, 2033	DS U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	>A> 11192897	Dec 12, 2033	DS U-1700			
	>A> 11192897	Dec 12, 2033	DS U-1701			
	>A> 11192897	Dec 12, 2033	DS U-1948			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					I-881	Jun 17, 2024
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001					I-881	Jun 17, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	>A> 11273160	Apr 03, 2039	U-2952			
<u>RANOLAZINE - ASPRUZYO SPRINKLE</u>						
N 216018 002	>A> 10898444	Jan 24, 2038	DP			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	>A> 11266681	Jul 10, 2038	U-2984			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001 >A>	11266681	Jul 10, 2038	U-3249			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	>A> 11266681	Jul 10, 2038	U-2984			
	>A> 11266681	Jul 10, 2038	U-3249			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11247969	Mar 10, 2025	DP			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001					NPP	Dec 10, 2024
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001 >A>	11266635	Aug 12, 2040	U-3330			
<u>RIVAROXBAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXBAN - XARELTO</u>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP		NP PED	Dec 20, 2024 Jun 20, 2025
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11219624	May 20, 2031	DP U-3229			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		NPP	Jan 26, 2025
	10335390	Sep 04, 2035	DP U-3270			
	10682338	Sep 04, 2035	DP U-2583			
	10682338	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			
	10857133	Sep 04, 2035	DP U-2583			
	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	>A> 11253494	Mar 15, 2033	U-3323			
	>A> 11253494	Mar 15, 2033	U-3324			
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001					ODE* PED	Apr 07, 2024 Oct 07, 2024
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002					ODE* PED	Apr 07, 2024 Oct 07, 2024
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	10519146	May 21, 2038	DS DP			
	11236091	May 20, 2040	DS DP U-3306			
<u>SUCRALFATE - SUCRALFATE</u>						
A 211884 001					>A> CGT	Sep 11, 2022
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592 001					CGT	Aug 25, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592 002					CGT	Aug 25, 2022
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2023	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2023	DS DP U-3100			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					I-879	Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002					I-879	Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	>A> 11253523	Mar 14, 2034	U-3326		I-879	Dec 14, 2024
	>A> 11253523	Mar 14, 2034	U-3327			
	>A> 11253523	Mar 14, 2034	U-3328			
	>A> 11253523	Mar 14, 2034	U-3329			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	>A> 11253523	Mar 14, 2034	U-3326			
	>A> 11253523	Mar 14, 2034	U-3327			
	>A> 11253523	Mar 14, 2034	U-3328			
	>A> 11253523	Mar 14, 2034	U-3329			
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 206119 001					>A> PC	Sep 06, 2022
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001					M-271	Jun 24, 2024
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176 001	10981919	Jul 02, 2033	U-3063			
	10981919	Jul 02, 2033	U-3064			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10995095	Oct 17, 2036	U-3298		I-880	Dec 14, 2024
	8962629	Jan 15, 2031	DS U-3255		I-883	Jan 14, 2025
	8962629	Jan 15, 2031	DS U-3275			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	10344036	Oct 17, 2036	DP		I-883	Jan 14, 2025
	10550126	Oct 17, 2036	U-3298		NCE	Aug 16, 2024
	10730883	Oct 17, 2036	DP			
	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003					>A> NCE	Aug 16, 2024
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11224598	Oct 19, 2035	U-1900			
<u>VASOPRESSIN - VASOPRESSIN</u>						
A 211538 001					PC	Jul 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004					M-232	Jan 28, 2025

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 42ND Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm